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Abstract
Mechanistic Insight into Chronic Stress-Induced Cerebrovascular Dysfunction
Emily N. Burrage

Despite decades of research psychological stress remains a prevalent problem in
society, often diminishing quality of life and increasing the risk of developing dementia.
The brain plays a central role in the response to stress and as it is unable to store energy
substrates, the brain relies heavily on dynamically regulated blood flow. Therefore, it is
important that there is a tight coupling between neural activity and cerebral blood flow to
meet metabolic demands and maintain critical brain function. It has been established that
chronic psychological stress has detrimental effects on cerebrovascular function,
potentially through increased superoxide anion production through the xanthine oxidase
(XO) pathway. While the alterations to cerebrovascular function and increased oxidative
stress have been well-defined, there is no evidence of a mechanism behind such
alterations. Therefore, there is a critical need to identify the mechanism linking chronic
stress and cerebrovascular dysfunction as well as the potential role of the XO pathway.
The projects specific aims are:
1. Specific Aim 1: To test the hypothesis that the xanthine oxidase pathway
mediates the cerebrovascular dysfunction associated with chronic stress.
A. Determine the impact of complete inhibition of the XO pathway by means
of a novel drug, febuxostat, on cerebrovascular function in a model of
chronic stress.
B. Examine the impact of pharmacological manipulation of the xanthine
oxidase pathway through a sodium nitrite supplementation on
cerebrovascular function in a model of chronic stress.
2. Specific Aim 2: To test the hypothesis that toll-like receptor 4 activation
plays a central role in exacerbating the cerebrovascular dysfunction with
chronic stress.
3. Specific Aim 3: To test the hypothesis that chronic stress accelerates
Alzheimer’s disease-related cerebrovascular dysfunction in a triple
transgenic mouse model.
The results of these studies have helped to gain an understanding of the
mechanisms driving cerebrovascular dysfunction with chronic stress. By thoroughly
interrogating these mechanisms and applying them to a model of Alzheimer’s disease,
this dissertation hopes to lay the groundwork for assessing the impact of chronic stress
on accelerating the pathology of Alzheimer’s disease and elucidating a potential
mechanism behind this pathology.

Dedication
This dissertation is dedicated to those of us who wake up each morning and try our
hardest to fight our demons.

iii

Acknowledgments
Through my many years at WVU I have met many incredible people who have
contributed to who I am as a scientist and a person. The individuals in this section have
aided me in this journey and I am entirely grateful for their support, of which without none
of this would have been possible.
I want to sincerely thank my family for their support throughout this entire journey.
Not once have they wavered in their support and love for me as I struggled through
personal challenges. Knowing my family had my back was one of the few things that kept
me going. I will always treasure their trips down to visit me, my trips to visit them, and the
many adventures we undertook.
Next, I want to thank my mentor, Dr. Paul Chantler. When I joined his lab five years
ago, he had no clue what he was getting himself into. Through the ups and the downs,
we have both grown as people and I would not be who I am as a scientist without his
guidance and support. He allowed me to follow my passion in neuroscience while also
exposing me to a new field of research and I will always be grateful for that. Along with
Paul, these passions were further supported by the members of my committee, Dr.
Courtney DeVries, Dr. James Simpkins, Dr. Mark Olfert, and Dr. Candice Brown, who
were always there to guide me on my way to becoming a better scientist.
I would also like to thank past and present lab members of both Chantler and Olfert
lab. We often worked very closely together, and we managed to create a fun yet
productive environment that I enjoyed working in. I also want to thank the 30+
undergraduate students I had the opportunity to work with; most of this research would

iv

have been impossible without the manpower and it was an honor being part of your first
introduction to research.
A special thanks also must go out to all the friends I’ve gathered throughout my
time here who have made a challenging journey much more bearable. Krista Garner, my
journey through grad school would have been a lot different without your friendship; I’ll
never forget our trips to Los and our binging of true crime and 90-day fiancé. I’ll always
treasure the memories I made with you through grad school and can’t wait to make more.
Finally, I would like to thank Mr. Wright and Dr. Princy Quadros-Mennella. I met
Mr. Wright in middle school, and he identified and fostered my initial love of science. I’ve
always been stubborn, but I’ll admit you were onto something when you told me to follow
a career in research. Dr. QM was there to pick up where Mr. Wright left off and I’ll never
forget the crazy look from Dr. QM when I told her I was taking a neuroscience class for
fun. She provided me with a fantastic foundation for my love of neuroscience and guided
me into the next chapter of my career.

v

Table of Contents
Mechanistic Insight into Chronic Stress-induced Cerebrovascular Dysfunction ......................................i
Abstract ............................................................................................................................................. ii
Dedication ........................................................................................................................................ iii
Acknowledgments ............................................................................................................................ iv
Table of Contents .............................................................................................................................. vi
Glossary of Abbreviations ................................................................................................................ vii
Chapter 1: Literature Review .............................................................................................................. 1
Chapter 2: Xanthine Oxidase Mediates Chronic Stress-Induced Cerebrovascular Dysfunction ............. 41
Chapter 3: Nitrite Supplementation Restores Cerebrovascular function with Chronic Stress ............... 83
Chapter 4: Toll-like receptor 4 Mediates Chronic Stress-Induced Cerebrovascular Dysfunction ......... 121
Chapter 5: Chronic Stress Accelerates the Progression of Cerebrovascular Dysfunction with
Alzheimer’s Disease: A Preliminary Study ....................................................................................... 151
Chapter 6: Dissertation Discussion .................................................................................................. 174

vi

Glossary of Abbreviations
4-Hydroxy-Tempo
Acetylcholine
Alzheimer’s Disease

(TEMPOL)
(ACh)
(AD)

Corticotropic Releasing Hormone

(CRH)

Endothelial Dependent Dilation

(EDD)

Endothelial Independent Dilation

(EID)

Endothelial Nitric oxide synthase

(eNOS)

Febuxostat
Glycosaminoglycans

(Feb)
(GAGs)

Hydrogen Peroxide

(H2O2)

Hypothalamic Pituitary Adrenal (axis)

(HPA)

L-NG-nitroarginine methyl ester
Middle Cerebral Artery
Nitric Oxide
Nitrite
Phenylephrine

(L-NAME)
(MCA)
(NO)
(NO2-)
(PE)

Physiological Salt Solution

(PSS)

Reactive Oxygen Species

(ROS)

Sodium Nitroprusside

(SNP)

Superoxide Anion

(O●-2)

Tumor Necrosis Factor Alpha
Toll-like receptor 4
Unpredictable Chronic Mild Stress
Xanthine Dehydrogenase
Xanthine Oxidase
Xanthine Oxidoreductase

(TNF-α)
(TLR4)
(UCMS)
(XDH)
(XO)
(XOR)

vii

Chapter 1
Review of Literature
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Dementia
Dementia is a major neurocognitive disorder and is characterized by a progressive
decline in one or more cognitive domains that interferes with a person’s ability to function 1.
Currently, more than 55 million people live with dementia worldwide, and this number is
projected to rise to 139 million by 20502. Alzheimer’s disease (AD) is the most common
form of dementia with it contributing to more than 60% of dementia cases2. AD is typically
characterized by amyloid plaques and neurofibrillary tangles; however, these
neuropathological changes occur in individuals with other forms of dementia as well as
cognitively healthy individuals3. It is this reason why new research into the pathology of
Alzheimer’s disease and other forms of dementia are being complete.
In 1991, cerebral microvessel alterations were discovered in patients with AD,
including focal constriction in terminal arterioles, irregular shape of smooth muscle cells,
and irregular surface of capillaries4. This observation was congruent with functional
studies in which transcranial doppler revealed impaired autoregulation and vasoreactivity
in patients with sporadic AD5 while continuous arterial spin-labeling magnetic resonance
imaging showed decreased resting cerebral blood flow in the posterior cingulate gyrus,
left inferior parietal, left lateral frontal, left superior temporal, and left orbitofrontal cortices
and increased resting cerebral blood flow right anterior cingulate gyrus, suggesting
dysregulation of blood flow with AD6. With these insights into dementia, researchers
began to assess the timing of these vascular alterations in relation to cognitive decline.
Epidemiological studies, such as the Rotterdam Study and the Honolulu-Asia Aging
Study, suggest arterial alterations are early events in cognitive deficits and one of the
strongest brain pathologies associated with Alzheimer’s disease 7,8. Similarly, work in a
2

transgenic mouse model of AD showed alterations in brain microvasculature prior to the
onset of cognitive changes, suggesting vascular alterations were developing before the
typical dementia pathology9. Taken together, these data revealed a new avenue of
research into dementia and Alzheimer’s disease coined “vascular contributions to
cognitive impairment and dementia” (VCID)10–12. Within this concept of VCID, it is thought
that typical dementia pathology results from alterations within the cerebral circulation that
result in glial and neuronal changes, eventually resulting in neurodegeneration, cognitive
decline, and dementia13. Taken together, these data implicate cerebral alterations as a
possible biomarker of AD severity and progression, especially in the asymptomatic phase
of the disease.
Another avenue of research that has gained traction recently is understanding the
relationship between stress and Alzheimer’s disease. Excessive levels of stress have
been known to exacerbate disease in large part through activation of the HPA axis 14. In
line with this, animal models of stress have been seen to increase the expression of
amyloid

precursor

hyperphosphorylated

protein,
Tau15–19.

the

generation

Corticosterone

of

Aβ

peptide,

injections

and

and

levels

of

manipulations

of

corticotropin-releasing factor were also sufficient to alter these AD endpoints 20–22.
Epidemiological studies revealed that early-stage AD-related dementia is associated with
dysregulated HPA axis; patients with mild cognitive impairment were noted to have
increased cortisol levels compared to age match controls23 and dementia patients were
noted to have impaired negative feedback of the HPA axis24, suggesting hyperactive HPA
axis may be an indicator of more advanced disease25. Taken together, these data suggest
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the usefulness of utilizing markers of cortisol dysregulation as a preclinical marker of
cognitive decline and further progression into dementia.
Animal models of Alzheimer’s Disease
As mentioned above, AD is characterized by extracellular amyloid plaques, made
of amyloid-β and intracellular neurofibrillary tangles, made of hyperphosphorylated tau 26.
Familial AD is due to mutations in one-off three genes: presenilin (PS) 1 and 2 and the
amyloid precursor protein (APP); whereas the genetic contribution of sporadic AD is
unknown27. With this knowledge, several animal models of AD have been generated,
including transgenic mice overexpressing different AD-associated proteins28. However, it
wasn’t until 2003 that a transgenic mouse model overexpressing all three genes found in
familial AD was created27.
To create these mice, human APPSwe and tauP301L were injected into PS1M146V
knockin mice29. These were the first strain of transgenic mice that displayed both plaque
and tangle pathology in AD-related areas of the brain, with the plaques forming before
the tangles29. These mice have been shown to recapitulate aspects of AD including agedependent cognitive decline and accumulation of plaques and tangles as well as
impacting male and female mice similarly27,29. Within this triple transgenic mouse model
of AD (3xTg-AD), plaques and cognitive decline are typically seen by 6 months of age,
and tangles developing by 12 months of age27. Interestingly, 3xTg-AD mice also display
cerebral microvessel alterations prior to the onset of plaques consistent with the theory
that cerebral alterations play a role in the development of AD pathology 30.
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The Cerebral Circulation
The brain, while only compromising about 2% of total body mass is the most
metabolically active organ requiring about 15-20% of total cardiac output31. This high
metabolic rate is due to the brains inability to store a sufficient amount of energy and
nutrients required to function32. In order to maintain consistent blood flow and meet the
energy demands of the brain, the cerebral circulation has a distinct anatomy with several
intrinsic, extrinsic, and autoregulatory mechanisms aimed at allowing for adaptation 31,33.
Anatomy of the Cerebrovasculature
The cerebral circulation of the brain is
supplied by two large pairs of arteries; the
left and right internal carotid arteries and the
left and right vertebral arteries31,34. The
internal carotid arteries primarily provide
blood flow to the cerebrum while the
vertebral arteries coalesce to form the
basilar artery which provides blood flow to
the cerebellum and brain stem31. These
arteries merge into a looping network of
communicating arteries, known as the circle
Figure 2: Arterial Circulation in the Brain

of Willis; this anastomotic ring structure

(Figure created with BioRender.com)

ensures the maintenance of blood flow by
creating a redundancy so the reduction of blood supply from one of these arteries is
compensated by the other two31,35.
5

Branching from the circle of Willis are three pairs of large pial arteries: the anterior,
middle, and posterior cerebral arteries (ACA, MCA, and PCA, respectively), which form
the beginning of the arterial network responsible for providing blood flow to corresponding
regions of the brain. These pial arteries progressively divide into smaller arteries and
arterioles that lay on the surface of the brain within the pia-arachnoid or the glai
limitans31,36.These pial arteries are located in close enough proximity to be able to provide
overlapping blood flow to neighboring arteries, allowing for redundancy of blood flow in a
phenomenon known as “collateral blood flow”. This phenomenon allows for compensation
of blood flow by neighboring arteries if a single pial arteries is experiencing a reduction or
blockage of blood flow31,37–39. Penetrating arteries branch from pial arteries and begin to
dive deeper in the brain, occupying a space known as the Virchow-Robin space. Once
these vessels penetrate deep enough into the brain, they become known as parenchymal
arterioles31. In contrast to pial arteries, parenchymal arterioles are surrounded by
astrocytes, a key hallmark of the blood brain barrier (BBB), intrinsically innervated by
brain neuropil, possess greater basal tone with less responsivity to various
neurotransmitters, and do not form an effective collateral network meaning the blockage
of one individual arteriole results in significant changes in blood flow31,40–42.
All arteries and arterioles of the cerebral circulation consists of three layers: the
tunica intima, the tunica media, and the tunica adventitia. The tunica intima is comprised
of endothelial cells and the internal elastic lamina, the tunica media is comprised of
smooth muscle cells and the tunica adventitia is comprised of collagen fibers, fibroblasts,
perivascular nerves, pericytes, and astrocyte end feet31,34. Despite consistencies of
general structure, pial arteries and parenchymal arterioles have varying structural and
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functional components. Pial arteries have multiple layers of smooth muscle cells ranging
from twenty layers in the internal carotid artery to two to three layers in smaller pial arteries
while parenchymal arterioles have only one layer of smooth muscle cells31. The welldeveloped smooth muscle cell layer of pial arteries allows for significant regulation of
blood flow by controlling resistance. Pial arteries also receive extrinsic intervention via
neurotransmitters such as Nitric Oxide (NO), acetylcholine (ACh), norepinephrine (NE),
and serotonin (5-hydroxytryptophan or 5-HT) as well as circulating factors31,43.
Parenchymal arterioles on the other hand are intrinsically innervated by the neurons and
glial cells in which they are embedded, have no response to some neurotransmitters (e.g.
NE and 5-HT), and display higher levels of basal tone 31,43. Lastly, pial arteries form a
collateral network that allows for compensation in blood flow with the occlusion of an
individual artery whereas parenchymal arterioles are largely long and unbranched with
the occlusion of an individual arteriole resulting in changes of blood flow 31,41,42.
The parenchymal arterioles give rise to the capillary beds of the cerebral
circulation. These capillaries are composed of a single layer of endothelial cells and have
no smooth muscle cell layer31,44. Capillaries within the brain are constantly perfused and
this is governed by flow from the feeding arterioles with dilation of arterioles increasing
perfusion pressure and therefore increasing capillary flow31,43. The brain is a particularly
dense in capillarity and it has been estimated that nearly every neuron in the brain has its
own capillary demonstrating the importance of blood flow for normal brain function 31,45. In
fact, the density of brain capillaries varies significantly within the brain depending on
location and energy needs with environmental, pathological, and physiological states
impacting capillary density31,46. For example, chronic hypoxia activates angiogenic
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pathways, primarily driven by VEGF and HIF-1 resulting in an increased capillarity in the
brain47,48. Other pathological states such as obesity induce the rarefaction of cerebral
microvessels49–51 and impair angiogenic pathways preventing the formation of new
arterioles and capillaries52.

Regulation of the cerebrovasculature
Given the brain substantial metabolic rate, maintaining and regulating cerebral
blood flow is crucial to healthy brain function. In normal physiological states, total blood
flow is kept constant due to vascular resistance and driven by changes in vessel diameter;
in order to increase blood flow to active regions of the brain, upstream vessels need to
dilate or constrict to optimize blood flow and perfusion pressure across the whole
network31,33. To accomplish these calculated and coordinated changes in blood flow and
perfusion pressure, the cerebral circulation relies on cerebral autoregulation via myogenic
response, flow-metabolism coupling, and neurogenic regulation31,33.
The cerebral circulation relies on both extrinsic and intrinsic neurogenic regulation
as a means to regulate cerebral blood flow. The pial arteries on the surface of the brain
undergo extrinsic innervation via the trigeminal ganglion, the superior cervical ganglion,
and the sphenopalatine ganglion; these ganglions carry sensory, sympathetic, and
parasympathetic nerve fibers, respectively33. Sympathetic innervation by these nerves
occurs via norepinephrine and serotonin although it is hypothesized that sympathetic
innervation has little impact on resting cerebral blood flow, instead it serves as a failsafe
against chronic hypertension by shifting the myogenic curve upwards and preventing
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edema and autoregulatory breakthrough31,33,53. Parasympathetic innervation by these
nerves occurs via NO and ACh and increases cerebral blood flow, preventing against
ischemia31,33.
Penetrating and parenchymal arterioles lack the nerve bundles associated with
pial arteries and therefore respond differently to extrinsic innervation. For example, pial
arteries have α1-adrenoceptors and 5-HT1B receptors which cause vasoconstriction,
however, in parenchymal arterioles these receptors are replaced by β1 adrenoceptors
and other 5-HT receptor subtypes which cause dilation in the face of NE and 5-HT31.
These arterioles are therefore more reliant on intrinsic innervation through astrocytes,
glial cells, and local interneurons33. Interestingly, both electrical stimulation and
optogenetic stimulation of GABA interneurons within the cortex was sufficient at causing
vasodilation46,54,55.
The myogenic response is an intrinsic property of vascular smooth muscle cells to
respond to changes in cerebral perfusion pressure with increases in pressure resulting in
vasoconstriction and decreases in pressure resulting in vasodilation31,33. The myogenic
response first serves to establish and maintain vascular tone so that the vasculature may
dilate or constrict in order to regulate perfusion; this phenomenon is known as myogenic
tone. Myogenic tone typically develops at 40-60mmHg and is characterized by an
increase in intracellular calcium, such that inhibition of intracellular calcium prevents the
development of myogenic tone56–58. Anything below this tone and the vessel becomes
reliant on changes in blood pressure as it cannot further dilate without risk of
collapsing57,59. The myogenic reactivity phase exists at 60-140mmHg. During this phase,
increases in pressure result in mild constriction and decrease in pressure result in mild
9

dilation with little overall change in vessel diameter. This phase is characterized by a
relatively small increase in calcium production along with increased sensitivity to calcium
possibly via activation of protein kinase C and RhoA-Rho kinase pathways31,56,57,60. Once
pressure reaches about 140mmHg, the vessels undergo forced dilation; this process
results in loss of myogenic tone, increases in vessel dimeter, and elevated calcium 56,57.
It is likely that this process is driven by active vasodilation via K Ca channels and NO to
protect the arterial wall from damage57.
Metabolic autoregulation, also referred to as functional hyperemia or flowmetabolism coupling, is also an important method of controlling cerebral blood flow.
Metabolic autoregulation has been observed repeatedly in various imaging modalities and
is the idea that cerebral blood flow varies with cerebral metabolism; this idea is particularly
important as the brain is quite vulnerable to ischemia33,61. There are many molecules
thought to be involved with metabolic autoregulation including potassium, hydrogen, and
adenosine33. Adenosine has been proposed as the primary metabolite responsible for
maintaining metabolic autoregulation within the cerebral circulation. It is produced as a
byproduct of ATP metabolism therefore its accumulation signals a need for increased
blood flow33,57. In fact, topical administration of adenosine within the cerebrovasculature
results in vasodilation likely through the A2A receptor62 and inhibition of this same receptor
in the presence of glutamate, a major neurotransmitter within the central nervous system,
prevents vasodilation63. Potassium and hydrogen are known byproducts of neuronal
synaptic activity and elevations of these ions are known to stimulate vasodilation33,57.
Acute hypoxia, which causes a decrease in ATP levels, causes KATP channels to activate
in vascular smooth muscle cells, allowing an efflux of K+, resulting in hyperpolarization of
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smooth muscle cells and vasodilation of the vessel31. Similarly, increases in carbon
dioxide results in increased H+ and promotion of vasodilation31.

Adenosine

NO

H+

K+

VIP

Figure 4: Cerebrovascular Regulation (Figure created in BioRender.com)

Psychological Stress
The meaning of stress is ambiguous in nature and often refers to predominantly
negative life events. Stress is defined as a subjective perception of an adverse
environmental stimulus and leads to a state of threatened homeostasis aimed at allowing
for adaptation64. This response is typically driven by activation of the autonomic nervous
system and the hypothalamic-pituitary-adrenal (HPA) axis and these responses promote
adaptation through allostasis or the reestablishment of homeostasis 65. In short term,
these responses are adaptive and advantageous; however, chronic exposure to stress
leads to allosteric overload, resulting in maladaptive responses in various body systems

11

and activation of pathophysiological mechanisms65. In fact, 75% of Americans report
experiencing psychological stress with 28% of them reporting that stress has a negative
impact on their mental health and 25% reporting a negative impact on their physical
health, identifying stress as a leading disease burden66.
As mentioned above, the stress response is primarily driven by activation of the
autonomic nervous system and the HPA axis. Activation of the sympathetic component
of the autonomic nervous system is often referred to as the “fast” component of the stress
response whereas activation of the HPA axis is referred to as the “slow” component of
the stress response67. Activation of the sympathetic nervous system results in increased
secretion of epinephrine and norepinephrine into the bloodstream from the adrenal
medulla68. This increased secretion of epinephrine and norepinephrine increases heart
rate, blood pressure, and respiratory rate, all reflective of the typical “fight-or-flight”
response68,69. Further, the release of norepinephrine specifically may be involved in the
regulation of the HPA axis as injection of norepinephrine results in a rapid increase in
corticosterone production70–72.
Activation of the HPA axis results in the release of corticotropin-releasing hormone
(CRH) from the paraventricular nucleus of the hypothalamus which facilitates the release
of adrenocorticotropin hormone (ACTH) from the anterior pituitary. ACTH then stimulates
the adrenal cortex to secrete cortisol (in humans) and corticosterone (in humans, rats,
and mice) into circulation. Circulating cortisol and corticosterone facilitate a cascade of
physiological changes including increased blood flow, metabolism, and gluconeogenesis
to further the “fight or flight” response. Under normal conditions, a negative feedback loop
exists such that secretion of cortisol/corticosterone, as well as catecholamines, result in
12

the inhibition of this pathway; this negative feedback loop allows the body to return to a
state of allostasis68.
Although

allostatic

restoration is the goal of the
stress response, chronic stress
leads to dysfunction of this
response. In states of chronic
stress, the negative feedback
mechanism is removed, and the
body becomes over-sensitized to
stressors resulting in allosteric
overload65. The removal of this
brake

mechanism

detrimental

has

physiological

consequences on various body
Figure 5: Physiological Stress Response (Burrage 2018, Brain
Circulation)

systems, specifically within the
cardiovascular

and

cerebrovascular systems. This “exhaustion stage” of the stress response leads to longterm elevation of blood pressure and heart rate increasing the risk of coronary artery
disease, stroke, and hypertension67. Chronic stress has also been known to weaken the
immune response due to the suppressive effects of stress hormones on cells in the
immune system, further leaving the body susceptible to future insults73. Taken together,
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chronic stress disrupts typically homeostatic responses, increasing the risk of developing
cardio and cerebrovascular diseases.
The Unpredictable Chronic Mild Stress (UCMS) protocol is one of the most widely
accepted models of chronic stress in rodents. UCMS provides an accurate indicator of
allosteric overload by promoting sensitization while preventing habituation to stressors
through a consistent and randomized stress exposure. It has been well documented that
the UCMS paradigm provides sufficient activation of the HPA axis and the autonomic
nervous system and elicits clinically relevant symptoms of chronic stress74–77.
Physiological Stress and the Cerebrovasculature
Regulation of cerebral blood flow is regulated by intrinsic control mechanisms
(myogenic, chemical, metabolic, and neurogenic responses) that match cerebral blood
flow to metabolic demand. During acute stresses, norepinephrine improves the
communication between neuronal activity and metabolic need, thus stimulating an
increase in cerebral blood flow in more active areas of the brain. This was seen by Wang
et. al. who utilized perfusion functional MRI to show acute stress increases cerebral blood
flow in the ventral right prefrontal cortex and left insula/putamen area78. Interestingly,
subjects with a high-stress response displayed sustained activity within these areas well
after the stress task was complete78. Alternatively, recent work within an animal model of
chronic stress showed decreased cerebral blood flow within the somatosensory cortex in
response to a hindlimb shock, with specific emphasis on decreased reactivity in pial
arteries, possibly due to dysfunctional rectifying potassium channels in endothelial
smooth muscle cells79,80. Overall, these data suggest heterogeneous alterations to the
hemodynamic response in states of chronic stress, with some regions being more
14

sensitive and others being desensitized. Similarly, it has been noted that there are varying
responses of the blood brain barrier to stress, with the cerebrovasculature being one of
the main structural components of the blood brain barrier. Typically, acute stress does
not increase blood brain barrier permeability81 whereas the effect of chronic stress on
blood brain barrier permeability is debated within the field. Xu et.al. show blood brain
barrier hyperpermeability within the amygdala of rats exposed to chronic restraint stress 82
and Santha identifies hyperpermeability of the blood brain barrier within the frontal cortex
and hippocampus83. However, other groups have noted no blood brain barrier dysfunction
in models of chronic stress81,84 while others have noted blood-brain barrier dysfunction
only in susceptible mice as opposed to resilient mice85.
Previous work in our lab has shown that eight weeks of chronic stress induces
cerebral endothelial dysfunction in a lean rat model and eight weeks of chronic stress in
an obese model induces smooth muscle cell dysfunction in addition to endothelial cell
dysfunction50,86. These adaptions to chronic stress were coupled with increased levels of
oxidative stress and reduced nitric oxide bioavailability in the cerebral vessels. It is
thought that these adaptations are driven by the increased production of glucocorticoids.
Increased cortisol has been linked to decreased nitric oxide bioavailability directly by
inhibiting endothelial nitric oxide synthase and indirectly through cortisol-induced
oxidative stress87,88. Additionally, cortisol has been noted to delay cerebral smooth
muscle cell response to stimuli potentially via the previously mentioned mechanism as
well as an increase in proinflammatory cytokine production 89. As reviewed by Liu et. al.
and Maydych, stress is directly correlated to increased proinflammatory cytokine
production which has been linked to various cerebrovascular diseases 87,90. Specifically,
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within cerebral endothelial cells, Dudek et. al. showed increased inflammation within
endothelial cells derived from the nucleus accumbens followed by up-regulation of
epigenetic regulator hdac1, leading to loosened tight junctions and blood-brain barrier
permeability91. These findings were confirmed by Wang et. al. who noted decreased
expression of various tight junction proteins92.
Figure 6:
Cerebrovascular
dysfunction with
Chronic Stress
(Burrage 2018,
Brain Circulation)

Oxidative Stress
Reactive oxygen species (ROS) are a group of oxygen-derived molecules
generated by mammalian cells and include radicals such as superoxide anions (O2-∙) and
hydroxyl anions and nonradicals such as hydrogen peroxide (H2O2) and peroxynitrite93.
During physiological conditions, the production and metabolism of reactive oxygen
species are tightly regulated by antioxidants in order to prevent cell damage; under these
conditions, reactive oxygen species may serve as important signaling molecules for the
regulation of vascular tone. For example, superoxide anions and hydrogen peroxide can
both serve as vasodilators and vasoconstrictors in the cerebral circulation depending on
16

concentration and the presence of other reactive oxygen species 94. Within
cerebrovascular cells, there are many sources of reactive oxygen species including
mitochondrial electron-transport chain, cyclooxygenases, lipooxygenases, cytochrome
P450 reductases, xanthine oxidase, nitric oxide synthase, and Nox 95. However,
numerous stimuli can disrupt the oxidant/antioxidant balance resulting in oxidative stress
and oxidative stress is a hallmark characteristic of chronic stress that correlates with
several cardio and cerebrovascular diseases96,97.
Unfortunately, the brain is particularly susceptible to oxidative stress due to its high
levels of peroxidizable polyunsaturated fatty acids and transition metals, the low
antioxidant defense mechanisms, and the brain’s high demand for oxygen 98–100.
Interestingly, brain endothelial cells seem to possess a higher number of mitochondria
than peripheral endothelial cells, further increasing susceptibility to oxidative stress 101. A
major mechanism for the impact of oxidative stress on vascular function is the decrease
of nitric oxide bioavailability and/or signaling within the endothelium. It is widely described
that the reaction of superoxide anions and nitric oxide results in a decrease in nitric oxide
bioavailability thus diminishing its vasodilatory properties, anti-proliferative, and antiinflammatory properties95,96,102,103. It’s important to mention that this reaction also
produces peroxynitrite, a powerful oxidant that can cause damage to proteins and DNA
and impairs vascular response to nitric oxide104,105. Peroxynitrite also promotes eNOS
uncoupling by oxidizing tetrahydrobiopterin (BH4), a cofactor in nitric oxide synthesis, to
dihydrobiopterin (BH2)106; uncoupled eNOS will typically generate superoxide anions
instead of nitric oxide due to its low levels of BH4 cofactor107. Furthermore, increased
levels of hydrogen peroxide, a common cerebrovascular vasodilator, can act as a pro-
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apoptotic agent within cerebral vascular cells108. In addition, increased reactive oxygen
species can increase Rho-kinase signaling, interfering with eNOS expression and activity,
further impairing NO bioavailability and creating a vicious cycle in which increased Rhokinase activity leads to decreased NO which may further increase Rho-kinase
activity109,110.
On top of reactive oxygen species induced decrease in nitric oxide bioavailability,
reactive oxygen species have also been known to impact the second messenger systems
of the cerebral circulation. Increased superoxide anion production has important
consequences regarding the signaling properties of soluble guanylyl cyclase (sGC) and
the cGMP-dependent protein kinase I (cGK-I), whose activity has been shown to be
regulated in a redox-sensitive fashion111. Further, cyclic guanosine monophosphate, a
major second messenger within the smooth muscle cells responsible for activation of
Cgk-I, has been noted to be inhibited by reactive oxygen species, resulting in an impaired
vasodilatory response within the smooth muscle to nitric oxide as well as inhibiting further
downstream mediators such as protein kinase G, vasodilator-stimulated phosphoprotein,
and transient receptor potential channel 4112.
While oxidative stress is typically characterized as an increase in pro-oxidant
pathways, it is also characterized by a decrease in antioxidant pathways. The brain has
a powerful antioxidant defense system including glutathione (GSH), glutathione
peroxidase, glutathione reductase, superoxide dismutase, and catalase 104. In states of
oxidative stress, these pathways are underactive when compared to pro-oxidant
pathways, leading to the imbalance between pro-oxidant pathways and antioxidant
pathways which is a key characteristic of oxidative stress.
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It has been well characterized that chronic physiological stress is sufficient at
inducing an oxidative stress environment within the brain and cerebral circulation. In a
meta-analysis performed by Costantini et al, it was shown that glucocorticoids have a
significant effect on oxidative stress levels, with the brain being the most susceptible to
oxidative stress113. In animal models of physiological stress, the brain shows that
antioxidant capacity is decreased while pro-oxidant capacity is increased114–117.
Interestingly, in an animal model of social defeat, the effects of chronic stress varied
depending on the brain region. Increased levels of oxidative stress markers and
decreased pro-oxidant markers were noted in the hippocampus but not within the
amygdala or prefrontal cortex118.

Past work in our lab has shown cerebrovascular

dysfunction consistent with decreased nitric oxide bioavailability and increased
superoxide anions via dihydroethidium staining within the cerebral circulations,
implicating an oxidative nitric oxide pathway50. This was further supported by Lehmann
et. al. who isolated endothelial cells isolated from mice exposed to chronic social defeat;
in these endothelial cells, they identified an increase in gene expression for genes
associated with reactive oxygen species activity85. Taken together, it is clear that oxidative
stress plays a role in the dysfunction associated with chronic stress, however, the source
of oxidative stress has not been identified.

Xanthine Oxidoreductase
Previously gathered data has noted an increase in superoxide anion production in
response to chronic stress50 and while superoxide anions are produced through a variety
of pathways, work by Yisieyili et al. specifically noted an increase in xanthine
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oxidoreductase
(XOR)

in

mice

exposed to restraint
stress119.

Xanthine

oxidoreductase is a
name commonly used
to

describe

two

interconvertible forms
of the same enzyme:
Figure 8: Xanthine Oxidoreductase Pathway

xanthine
dehydrogenase and xanthine oxidase120. Xanthine dehydrogenase exists primarily
intracellularly and catalyzes the oxidation of hypoxanthine to xanthine to uric acid where
NAD+ is reduced to NADH. Xanthine oxidase exists primarily extracellularly and also
catalyzes the oxidation of hypoxanthine to xanthine to uric acid, however, the electrons
derived from this conversion are quickly accepted by O 2 to generate superoxide and
hydrogen peroxide121,122. Physiologically, xanthine dehydrogenase is the prevalent form
of xanthine oxidoreductase and is primarily transcribed and translated in the liver 120,123.
In pathophysiological conditions, such as inflammation and hypoxia, xanthine
dehydrogenase can be upregulated in one anatomical site (i.e. liver) and exported into
the circulation where it is converted to xanthine oxidase; as xanthine oxidase has a high
affinity for glycosaminoglycans (GAGs) on the apical surface of the vascular endothelium,
xanthine oxidase can enzymatically produce reactive oxygen species on the vascular
endothelium124,125. Interestingly, an increased accumulation of superoxide anions has
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been noted in various tissue beds such as liver, intestine, and visceral adipose tissue as
well as an increased level of superoxide anions within serum of mice exposed to chronic
stress119. These increased levels of superoxide anions, produced via xanthine oxidase,
are sufficient to induce a pro-oxidative stress environment, potentially eliciting endothelial
cell dysfunction, a hallmark characteristic of cerebrovascular dysfunction associated with
chronic stress.
Xanthine oxidoreductase is one of the most pharmacologically targeted sources of
reactive oxygen species as it can be specifically inhibited by FDA-approved compounds.
In 1966, allopurinol was approved by the FDA for the treatment of gout and is currently
still being used in the therapy for hyperuricemia126. While allopurinol is successful when
used in this capacity, it had little to no effect on vascular inflammatory diseases, likely due
to allopurinol’s enzymatic production of reactive oxygen species and its inability to inhibit
endothelial GAG-associated xanthine oxidase127. In 2009, febuxostat was approved by
the FDA for clinical use in treating gout. Febuxostat is significantly more potent than
allopurinol and is more physiological relevant; in addition, inhibition properties of
febuxostat remain constant for traditional XOR and endothelial GAG-bound xanthine
oxidase, making it ideal to aid in vascular inflammatory diseases128,129.
While the canonical pathway for nitric oxide production is via nitric oxide synthases
through the oxygen-dependent enzymatic conversion of arginine to citrulline, it is now
established that alternative pathways of nitric oxide production exist. One of these
pathways is the one-electron reduction of the nitrite anion to nitric oxide 130–133.
Interestingly xanthine oxidoreductase is one of the enzymes capable of catalyzing this
reaction108,134,135. It is speculated that nitrite may alter the byproducts of xanthine
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oxidoreductase from hydrogen peroxide and superoxide anions to nitrite oxide 136. In a
study run by Alef, et. al. nitrite supplementation was sufficient to increase nitric oxide
levels in carotid artery injured rats, however, inhibition of xanthine oxidoreductase via
allopurinol alongside nitrite supplementation prevented this increase in nitric oxide
bioavailability, suggesting the importance of xanthine oxidoreductase in the conversion
of nitrite to nitric oxide in vascular injury137. As chronic stress has been shown to increase
xanthine oxidoreductase levels, nitrite supplementation may be a viable treatment option,
allowing us to exploit this pathway into improving nitric oxide bioavailability, directly by
producing nitric oxide and indirectly by decreasing the production of reactive oxygen
species.

Figure 9: Nitrite Reduction to Nitric Oxide by Xanthine Oxidoreductase

The Immune Response
The immune system is the body’s intrinsic defense system against a pathogen it deems
foreign; when this pathogen is detected, the immune system utilizes a variety of cell types
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to eliminate the potential threat and reduce harm to the host. The immune system is
typically broken down into two branches: the innate immune response and the adaptive
immune response. The innate immune response is typically considered the general
immune response and acts quickly against foreign bodies and injuries. It is comprised of
skin, mucus membranes, and defense cells such as mast cells, dendritic cells, and
granulocytes. The adaptive immune response to much more specialized and therefore
slower to respond. It is comprised of T lymphocytes, B lymphocytes, and antibodies
targeted to specific pathogens or changed body cells.
The inflammatory response that is centralized within the peripheral nervous system
and central nervous system are typically referred to as neuroinflammatory responses.
This inflammatory response is typically mediated by the production of cytokines,
chemokines, reactive oxygen species, and secondary messengers, and these mediators
are produced by microglia, astrocytes, endothelial cells, and peripheral immune cells.
Similarly, to stress, the impact of inflammation depends on the context and duration. For
example, controlled neuroinflammation has been linked to increased immune
surveillance, enhanced plasticity, tissue repair, and neuroprotection 138. However,
maladaptive immune responses can lead to collateral damage, development of anxiety
or depression, reduced plasticity/cognitive impairment, and neuronal damage 138.
Microglia are the resident immune cells of the central nervous system and as such
performs the primary immune surveillance and engage in macrophage-like activities,
including the production of chemokines and cytokines. Microglia develop early on in
embryogenesis from myeloid precursor cells in the embryonic yolk sack and then migrate
to the central nervous system139. As they are derived from the same progenitor as the
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rest of the macrophages, microglia are long-lived cells that have limited turnover, making
them extremely susceptible to aging, stress, and injury140. At rest, microglia play an active
role in surveillance as seen by two-photon imaging studies that show microglia using their
processes to survey their environment141,142 and they play an important role in
propagating peripheral immune signals143. When microglia become active, they alter their
transcriptional profile and begin producing inflammatory cytokines and chemokines,
potentially facilitating leukocyte recruitment to the brain144. On top of this microglia also
undergo cytoskeletal rearrangements, altering receptor expression and allowing for
migration toward the site of injury and increasing phagocytic properties 142,145. All these
adaptations are meant to protect the central nervous system against injury, however,
amplified, exaggerated, and chronic activation can have pathological consequences.
Large bodies of evidence indicate that stress can activate an inflammatory
response in the brain and the periphery146–148. Communication between the
neuroendocrine system and immune systems exists such that stress-induced release of
glucocorticoids typically suppresses immune response149. Early work revealed that
glucocorticoids inhibited leukocyte proliferation and cytotoxicity as well as reduced the
expression of several pro-inflammatory cytokines (e.g., TNF-α, IL-6) while enhancing the
expression of anti-inflammatory cytokines (e.g. IL-10, TNF-β)150–152. However, recent
work has begun to show the pro-inflammatory impact of glucocorticoids on the immune
system153–155. Munhoz, et. al. has shown that chronic unpredictable stress, which is
sufficient to induce glucocorticoid production, enhances the LPS-induced NFκB activity,
increases iNOS, IL-1β, and TNF-α expression, and decreases IL-1ra, IL-10, and MKP-1
expression156. These effects were found to be glucocorticoid mediated as inhibition of
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glucocorticoid prevented these changes156. As the interaction between the immune
system and the HPA axis is typically driven by a negative feedback loop, stress may
impair this negative feedback loop, leading to the switch from immunosuppressive to
immunopotentiator148. Besides glucocorticoids, hormones from the sympathetic nervous
system have been shown to have effects on the immune system. Norepinephrine can
promote pro-inflammatory cytokine production through the phosphorylation of mitogenactivated protein kinases (MAPK) and NPY can elicit the production of TGF-β and
TNFα157–159.
In addition to peripheral inflammation, neuroinflammation is a key component of
the stress response. As microglia have both glucocorticoid and mineralocorticoid
receptors, they are extremely susceptible to chronic stress-induced increases in
glucocorticoids147. In fact, physiological stress exposure was linked to increased
microglial activation, elevated pro-inflammatory cytokines, and accumulation of
peripheral-derived macrophages and monocytes within the brain160. Specific inhibition of
microglia using minocycline prevents this increase in proinflammatory cytokines,
suggesting the importance of microglia in inflammation driven by chronic stress161.
Microglia also have a myriad of receptors that are responsible for maintaining their
neuroinflammatory response; one of these receptors is Toll-like receptor 4 (TLR4).

Toll-like Receptor 4
TLR4 belongs to the family of pattern recognition receptors and is located on
hematopoietic and nonhematopoietic cells including microglia, neurons, and endothelial
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cells. Its first identified function was
the

recognition

molecules

of

exogenous

from

pathogens;

however, recent work has shown it
also functions in the recognition of
endogenous molecules from injured
tissues and necrotic cells162. TLR4
signaling functions through two
different

pathways:

dependent
independent

and

a
a

pathway.

MyD88MyD88Both

pathways are triggered by ligandinduced dimerization of the TLR4
Figure 10: TLR4 signaling

receptor. TIR domains of the TLR4
receptor recruit MyD88 and MAL, which leads to the recruitment and activation of IRAK
and TRAF6, activating TAK1; from there MAPK and IKK are activated leading to the
activation and translocation of transcription factors such as NFκB resulting in the
production of proinflammatory cytokines. The MyD88-independent pathway involved the
recruitment of TRIF and TRAM which then activated TKAF3; from there TBK1 and IKKε
are recruited and lead to the activation and translocation of transcription factors such as
IRF3 resulting in the production of type 1 interferons. As TLR4 plays such an important
role in regulating neuroinflammation, it is important that signaling is tightly regulated to
retain tissue homeostasis.
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In a study conducted by Barsness, et. al. mice exposed to hemorrhagic shock had
an increased expression of TLR4 despite the lack of presence of traditional TLR4 ligands,
such as LPS, suggesting that other ligands for TLR4 may exist 163. On this note, many
have referred to TLR4 as a danger signal receptor in the “danger model” of innate
immunity; in this model, the immune system is more concerned with danger signals
released from cells in times of stress as opposed to exogenous pathogens 164. In support
of this, Lorne, et. al. showed direct binding of XO to TLR4 on the surface of neutrophils;
this provides a direct mechanism as to how xanthine oxidase derived superoxide anions
may result in the increased production of pro-inflammatory cytokines and NFκB activity
via a TLR4 dependent pathway165. Importantly, neutrophils lacking TLR4 that were
incubated with xanthine oxidase did not display increasing pro-inflammatory cytokines or
increased NFκB activity165. As oxidative stress and inflammation display a bidirectional
relationship, it is likely that the chronicity of stress results in compounding damage to the
cerebrovasculature.

Summary and Statement of Aims
Despite decades of research psychological stress remains a prevalent problem in
society, often diminishing quality of life and increasing the risk of developing dementia.
The brain plays a central role in the response to stress and as it is unable to store energy
substrates, the brain relies heavily on dynamically regulated blood flow. Therefore, it is
important that there is a tight coupling between neural activity and cerebral blood flow to
meet metabolic demand and maintain critical brain function. It has been established that
chronic psychological stress has detrimental effects on cerebrovascular function,
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potentially through increased superoxide anion production through the XO pathway.
While the alterations to cerebrovascular function and increased superoxide anion
production have been well-defined, there is no evidence of a mechanism behind such
alterations. Therefore, there is a critical need to identify the mechanism linking chronic
stress and cerebrovascular dysfunction as well as the potential role of the XO pathway.
To test the hypothesis, we will be utilizing pharmacological and genetic models to
manipulate the XO pathway and its downstream effects in models of chronic
psychological and environmental stress. The first specific aim will target the XO pathway
first by using the novel drug febuxostat to inhibit the production of superoxide anions and
hydrogen peroxide and secondly by exploiting the pathway with a sodium nitrite overload,
allowing for targeted use of the XO pathway to produce nitric oxide, a potent vasodilator,
as opposed to superoxide anions and hydrogen peroxide. The second specific aim will
investigate the role of toll-like receptor 4 as a potential downstream effect of increased
superoxide anions, thought to exacerbate the initial damage. The third specific aim will
explore the effects of chronic stress on cerebrovascular function in a model of
Alzheimer’s’ disease. Overall, as our understanding of dementia and Alzheimer’s disease
continues to grow, the importance of chronic stress and cerebrovascular dysfunction as
a preclinical marker is critical to understand. Taken together, the impact of this study will
further elucidate the mechanism behind stress induced cerebrovascular dysfunction in
healthy and unhealthy individuals, allowing potential therapeutic approaches to emerge.
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Abstract
Background: The aim of the study was to determine the role of xanthine oxidase (XO)
on stress-induced cerebrovascular dysfunction. We hypothesized that XO inhibition
would prevent cerebrovascular dysfunction with chronic stress.
Methods and Results: 18-week-old male/female C57BL/6 mice underwent 8 weeks of
control conditions or unpredictable chronic mild stress (UCMS) with or without febuxostat
(50mg/L), a XO inhibitor, in the drinking water. Excised middle cerebral arteries (MCA)
were mounted in a pressurize myobath and exposed to increasing concentrations of
acetylcholine (ACh). UCMS mice had a 28% impaired MCA dilation to ACh vs.
controls (p<0.0001). However, febuxostat treatment prevented the UCMS-induced
impaired ACh response in the MCA. We examined biomolecular free radical formation,
via immuno-spin trapping with DMPO, xanthine oxidoreductase (XOR) protein
abundance, and hydrogen peroxide production in the liver and brain. UCMS increased
total free radical formation, XOR protein levels, and hydrogen peroxide production in the
liver compared to control. UCMS increased hydrogen peroxide production in the brain
and cerebrovasculature. Free radical production and hydrogen peroxide levels were
similar to controls in the liver and brain of UCMS mice treated with febuxostat. Mice
exposed to UCMS also had impaired working memory (p<0.05) and febuxostat treatment
prevented this impairment.
Conclusion: These data suggest that the cerebrovascular dysfunction associated with
chronic stress may be driven by a pro-oxidative environment contributable to XO, which
leads to a reduction in working memory.
Key Words: UCMS, Middle Cerebral Artery, Oxidative Stress, Cognition
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Introduction:
Chronic psychological stress is a major global health-related burden1. Seventy-five
percent of Americans report experiencing psychological stress with 28% of these
individuals reporting that stress has a negative impact on their mental health, and 25%
reporting a negative impact on their physical health2,3. In fact, chronic stress has been
identified as a powerful risk factor in the development of various cerebrovascular diseases
such as stroke and dementia4,5, which are the leading cause of long-term disability, and
the second leading cause of death worldwide6, establishing chronic stress as a leading
disease burden.
We have previously shown that chronic stress in rats induces significant
cerebrovascular dysfunction as well as produces a substantial pro-oxidative
environment7,8. However, the source of this pro-oxidative environment leading to
cerebrovascular dysfunction with chronic stress is unknown. An increase in the xanthine
oxidase (XO) has been identified in the plasma and post-mortem brain tissue of
stress/depressed patients9,10. And in a pre-clinical model, Yisieyili et al.11 noted an
increase in oxidative stress alongside increased XO activity in the liver, visceral adipose
tissue, and intestines of mice exposed to restraint stress. Others have shown the
importance of the XO pathway in inducing arterial dysfunction in the context of
hypertension12, sickle cell disease13, and diabetes14. However, the role of XO in
psychological stress-induced cerebrovascular dysfunction has yet to be established.
Xanthine oxidoreductase (XOR) oxidizes hypoxanthine to xanthine and xanthine
to uric acid and exists in two forms: xanthine dehydrogenase (XDH) and xanthine oxidase
(XO)15,16. While XDH utilizes NAD+ as an electron acceptor, XO donates electrons to
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molecular oxygen resulting in the production of superoxide anions and hydrogen peroxide
and is most abundant during proinflammatory processes including chronic stress 15,16.
XDH is transcribed and translated with the greatest specific activity observed in the liver;
however, following hepatic stressors, such as inflammation, hypoxia, or ischemia, XDH
can be released from hepatocytes to the circulation where it is rapidly converted to XO by
plasma proteases17,18. XO has a high affinity for glycosaminoglycans (GAGs) on the
vascular endothelium, where its immobilization on the endothelial surface places it, in a
prime position to induce endothelial dysfunction via oxidant production19. As it is wellestablished that chronic stress induces cerebrovascular dysfunction via an increase in
oxidative stress7 and chronic stress has been noted to increase oxidative stress through
XO activity11, it is important to explore the role of XO mediating the cerebrovascular
dysfunction noted with chronic stress. Therefore, we hypothesize that XO inhibition would
prevent the cerebrovascular dysfunction noted with chronic stress (unpredictable chronic
mild stress (UCMS) paradigm) and reduce the pro-oxidative environment in the brain and
cerebrovascular system.

Methods:
Animals: Male and female C57BL/6J mice (stock no. 000664) were obtained from The
Jackson Laboratory (Bar Harbor, ME) at 15-16 weeks of age. At 18 weeks of age, all
animals were singly-housed and randomly assigned to one of the following groups for 8
weeks: 1) control (non-UCMS), 2) UCMS, 3) control+febuxostat, (con+Feb) 4)
UCMS+febuxostat (UCMS+Feb). All animals were fed standard chow and tap water ad
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libitum for all experiments. Protocols received prior approval from the WVU HSC Animal
Care and Use Committee.

Febuxostat Treatment: Vehicle (standard drinking water) or febuxostat (Axon Medchem
BV, Netherlands) was delivered daily in the drinking water at a concentration of 50mg/L.
The water was measured frequently to calculate the concentration of drug consumed daily
(∼5–6 mg/kg per day) which was shown to effectively inhibit XO20.

UCMS Protocol: Previous investigators developed the UCMS paradigm to elicit a chronic
stress phenotype in rodents21. The UCMS model is considered to be the most appropriate
rodent model to elicit a chronic stress phenotype, based on its ability to reproduce anxietylike behaviors as well as its ability to lead to the development of symptoms related to the
clinical consequences of chronic stress such as anhedonia, learned helplessness, and
memory impairment7,22–24. Our lab has successfully utilized this paradigm to elicit chronic
stress-induced vascular alterations7,23,24.
In UCMS groups, mice were exposed to the following mild environmental stressors in
randomly chosen sequences for 7 hours each day, 5 days/week, over the course of 8
weeks:
1. Damp bedding – 10 oz. of water was added to each standard cage
2. Bath – all bedding was removed and ~0.5 inches of water was added to the empty
cage. The water temperature was room temperature, ~24°C
3. Cage Tilt - cage was tilted to 45 degrees without bedding
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4. Social stress – each mouse was switched into a cage of a neighboring mouse
5. No bedding – all bedding was removed from the cage
6. Alteration of light/dark cycles –turning lights off/on in random increments for a
scheduled period.

Stress markers: At the time of death, plasma was collected, and corticosterone levels
were examined in triplicate according to the manufacturer's instructions (ELISA kit: Arbor
Assay, Item #K014). During the duration of the 8-week protocol, the rodent’s coats were
evaluated. Each week the mice were inspected for grooming habits25; the total cumulative
coat score was computed by giving an individual score of 0 (clean) or 1 (dirty) to eight
different body parts (e.g. head, neck, back, forelimbs, stomach, hindlimbs, tail, genitals).
Following the 8-week protocol, sucrose splash testing was performed to assess grooming
behavior. The sucrose splash test consisted of spraying a 10% sucrose solution on the
dorsal coat of a mouse in an empty cage; latency to begin grooming as well as frequency
were recorded for a total of 5 minutes26.

Behavior
Y-maze spontaneous alternation test: Following a 30-minute room acclimation period
under indirect dim illumination conditions (approximately 150 lx), short-term working
memory was assessed. Mice were placed in the three-armed, Y-shaped apparatus
(approximate arm length = 38 cm, width = 8.25 cm, height = 13.25 cm) and allowed to
freely explore for 8 min. Movement in the apparatus was recorded using the Anymaze

46

tracking software (Stoelting, Chicago, IL). The innate tendency of mice to spontaneously
alternate between the three arms and enter the least recently visited arm was assessed
by determining the percentage of successful alternations ((number of correct
alternations/(total arm entries − 2)*100). Other dependent variables recorded included
distance moved (m) and speed (m/s). The apparatus was cleaned of debris and olfactory
cues between each animal using an anti-bacterial disinfectant (Virkon, Pharmacol, CT).

Open field test: In this task, total movement in the area indicates general locomotor
ability27. The apparatus consisted of a clear plastic box (40 cm × 40 cm) surrounded by a
16 × 16 laser beam array (San Diego Instruments, CA) that allowed for the assessment
of movement in the horizontal axis. A second array placed 3.8 cm above the first beam
allowed for the assessment of locomotion in the vertical axis (rearing behavior). Following
a 30-minute acclimation to the testing room (approximately 1500 lx), each mouse was
placed in the center point of the arena and allowed to freely explore for 30 min. Total
horizontal movements via beam breaks in the arena and the number of vertical beam
breaks (rearing) were recorded.

Vascular reactivity/mechanics: Mice were euthanized, and the brain was carefully
removed from the skull and placed in cold physiological salt solution (PSS; 4ºC). Both
middle cerebral arteries (MCA), which supply ≈50% of the cerebral blood flow 28, were
dissected from their origin at the Circle of Willis and placed into an isolated microvessel
chamber (living systems) filled with PSS. Each MCA was subsequently doubly cannulated
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within a heated chamber (37°C) that allowed the lumen and exterior of the vessel to be
perfused and superfused, respectively, with PSS from separate reservoirs. The PSS was
equilibrated with a 21% O2, 5% CO2, and 74% N2 gas mixture and had the following
composition (mM): 119 NaCl, 4.7 KCl, 1.17 MgSO4, 1.6 CaCl2, 1.18 NaH2PO4, 24
NaHCO3, 0.026 EDTA, and 5.5 glucose. Any side branches were ligated. MCA diameter
was measured using television microscopy and an on-screen video micrometer.

Measurements of Vascular Reactivity in Isolated MCA: Following cannulation, MCAs
were extended to their in-situ length and were equilibrated at 70 mmHg mean arterial
pressure. Active tone at the equilibration pressure was calculated as (ΔD/Dmax) × 100,
where ΔD is the diameter increase from rest in response to Ca 2+-free PSS, and Dmax is
the maximum diameter measured at the equilibration pressure in Ca 2+-free PSS.
Following equilibration, the MCA dilator reactivity was assessed in response to increasing
concentrations of an endothelial-dependent dilator (EDD, acetylcholine; ACh, 10−9M –
10−4M), endothelial independent dilator (EID, sodium nitroprusside; SNP 10 −9M – 10−4M),
and a potent vasoconstrictor (phenylephrine, PE 10 −9M – 10−4M). To assess the effects
of NO on EDD, the MCA was acutely incubated (30 minutes) with L-NAME (10−4 M) and
the MCA EDD response to ACh was repeated. To assess the acute effects of oxidative
stress on modulating EDD, we acutely (30 minutes) incubated the MCA with: 1) XO
(40uM; purified by Eric Kelley’s lab) supplemented with xanthine (10uM, Sigma Aldrich,
cat# X2502); 2) TEMPOL (10−4M, Sigma Aldrich, cat# 176141); and 3) febuxostat (10mM;
Axon Medchem BV, Netherlands). Following completion of all procedures, the perfusate
and superfusate were replaced with Ca2+-free PSS and the passive diameter of the fully
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relaxed MCA was determined over an intralumenal pressure range of 5–140 mmHg at
20-mmHg pressure increments. After 7 min at each intraluminal pressure, the inner and
outer diameters of the passive MCA were determined. Media thickness, lumen and outer
diameters, and vessel cross-sectional areas (used as indicators of structural alterations
to the individual microvessel) were determined as follows: Media thickness (WT, μm) =
Outer diameter – lumen diameter (i.e., OD – LD); media-to-lumen (M:L) ratio = MT/LD;
Cross-sectional area (μm2) = Outer vessel area – lumen area. Myogenic tone was
assessed using the following formula: 1-(active diameter/passive diameter)*100

29.

NO-

dependent dilation was determined from the maximal EDD in the absence or presence of
L-NAME according to the following formula: NO-dependent dilation (µm) = Maximum
dilationACh - Maximum dilationACh+L-NAME.

Cerebral Microvessel Isolation: To explore the vascular signaling pathway, the mouse
brain was carefully removed, the MCA was dissected for pressure-myography, and then
the remaining cerebral microvessels (parenchymal and meninges vessels) were isolated
from the brain using the dextran centrifugation method. In brief, brain tissue was
homogenized in 1X PBS and centrifuged at 2960 rpm at 4°C. The supernatant, containing
parenchymal tissue was discarded; the pellet was resuspended and layered over 15%
Dextran (in 1X PBS) (Sigma Aldrich, Item #31390). Following a 30-minute centrifugation
at 4000rpm at 4°C, the supernatant was discarded, and the pellet was resuspended in
1% bovine serum albumin (BSA) in 1X PBS. The suspension was then passed through a
70um cell strainer with the microvessels being collected on the mesh. The microvessels
were then washed with 1% BSA in 1X PBS and collected by centrifugation at 3000 rpm
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for 10 min at 4°C. Following this, microvessels were rinsed with 1X PBS, centrifugated at
4000 rpm for 5 min at 4°C, and flash frozen for future use (adapted from 30).
Tissue Oxidants: As briefly described below, the brain, liver, and microvessels were
explored for oxidative products. Tissue samples were dissected, flash froze in liquid
nitrogen, and stored at -80°C until analysis.

Xanthine Oxidase-HPLC: Plasma, liver, and brain tissue XO activity was measured
as previously described using high-performance liquid chromatography (HPLC)13,20.
Frozen samples were homogenized in ice-cold RIPA containing a protease inhibitor
cocktail (Sigma) and briefly spun down. Tissue samples were processed as described
below with a sample volume of 10µL. Uricase was inhibited by oxonic acid (100 µM) to
avoid an underestimation of enzyme activity. Total XOR activity was determined on the
basis of the rate of uric acid production in the presence of xanthine (75 µM) and
nicotinamide adenine dinucleotide (NAD+, 0.5 mM; for tissue samples only). Allopurinol
(100 µM), an inhibitor of XOR, was used in parallel samples to confirm that urate formation
was specific. After 60 min of incubation at 37°C, the reaction was terminated by protein
precipitation with cold acetonitrile. The samples were then centrifuged for 12 min at
11,900rpm, at 4°C. Following centrifugation, the supernatant was removed and placed in
borosilicate glass tubes. After a 60-minute dry-down process, the samples were
resuspended in the isocratic mobile phase (300 µL) and filtered through a 0.20 µm nylon
membrane filter unit into an 11 mm plastic snap top auto-sampler vials. The uric acid
content of protein-free samples was determined by an HPLC-based electrochemical
technique as described below. One unit of activity (U) is defined as 1 µmole/min urate
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formed at 37°C and pH 7.4. Total protein concentration was determined by the
bicinchoninic acid method (BCA, Pierce). Measurements were carried out blindly without
knowledge by the operator of the animal treatment groups. Uric acid was measured by
electrochemical detection (Vanquish UltiMate 3000 ECD-3000RS) coupled to reversephase HPLC using a Phenomenex column (Luna 3µm C18(2) 100 A, 150x4.6 mm) and
isocratic

mobile

phase

(50

mM

sodium

dihydrogen

phosphate,

4

mM

dodecyltrimethylammonium chloride, 2.5% methanol, pH 7.0). Potentials for 3 channels
were as follows: -100mV, 30mV, and 390mV. Quantitation/integration was performed on
the dominant peak. In the case of XO activity in plasma, 10-20 µL of plasma was used in
lieu of tissue and processed with the same protocol as above. XO activity in plasma
utilized volume (U/mL) as a denominator rather than protein.

Xanthine Oxidase-Western Blots: Liver and brain tissue was homogenized in 1X
PBS plus HALT inhibitor and then centrifuged at 3000 rpm at 4 °C for 20 min. Equal
amounts of protein for each sample were loaded into a polyacrylamide gel. After the
completion of gel electrophoresis, the protein was transferred to nitrocellulose
membranes overnight. XO expression was assessed using a xanthine oxidase antibody
(1:500; Santa Cruz; cat # sc-398548) followed by a secondary antibody (1:10,000; Licor;
cat # 925-32201 and 925-68071). GAPDH (1:1000; Cell Signaling; cat #2118) was used
as a loading control. Blots were imaged using Licor Odyssey and band intensity was
assessed using ImageJ software.
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Coumarin Boronic Acid (CBA) Assay: Hydrogen peroxide (H2O2) abundance was
measured in homogenate from the liver, brain, and brain microvessel using the CBA
(Cayman #14051) assay adapted from Zielonka et. al31 as previously described32,33. In
brief, 10μg of lysates were loaded, in triplicate, into wells of a 384-well black-sided clear
bottom plate. Subsequently, assay buffer composed of HBSS supplemented with 25 mM
HEPES, 1% BSA, 10uM DTPA, 100uM l-NAME, and 1 mM Taurine was added and then
CBA was added to each well at a final concentration of 0.5 mM. One well from each
biological sample received an additional 1 KU/ml bovine liver catalase to act as a negative
control. Upon addition of the CBA, plates were placed in a Biotek plate reader preheated
to 37°C and read kinetically at excitation 350 nm and emission 450 nm. The average rate
of fluorescence was determined over the linear portion of the response and then
normalized by subtracting out the rate of fluorescence from the negative control and
taking the fold change from the control group.

In Vivo Immuno-Spin Trapping: In a separate set of mice (3/sex/group), an i.p
injection of 5,5-Dimethyl-1-Pyrroline-N-Oxide (DMPO: 1.5g/kg) in 3x0.5 g/kg doses was
given at 24, 12, 6 hours prior to euthanasia, as previously reported 34,35. Upon
euthanization, organs/tissues were perfused with phosphate-buffered saline (PBS; pH
7.4), removed, frozen in liquid N2, and stored at −80°C for Western blot analysis. Liver
and brain tissue were homogenized in RIPA buffer plus HALT inhibitor and then
centrifuged at 3000 rpm at 4 °C for 20 min to remove insoluble materials. An equal amount
of protein for each sample was loaded into a polyacrylamide gel. After the completion of
gel electrophoresis, the protein was transferred to nitrocellulose membranes overnight.
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DMPO-adducted proteins were assessed using mouse anti-DMPO (1:500, Enzo Life
Science, Item #ALX-803-340) followed by a secondary antibody (1:10,000; Licor; cat #
925-32201 and 925-68071). GAPDH (1:1000; Cell Signaling; cat #2118) was used as a
loading control. Blots were imaged using Licor Odyssey and band intensity was assessed
using ImageJ software.

Statistics: Data are presented as mean ± SD unless otherwise stated. Normality was
evaluated by the Kolmogorov–Smirnov test, and outliers were identified using ROUT
analysis with a Q=1% and excluded from data presentation. As no statistical differences
were noted between male and female mice for all variables, male and female data were
combined for statistical approaches. The MCA maximal reactivity or the MCA remodeling
was analyzed by a multifactorial (experimental condition i.e., Control, UCMS, Con+Feb,
and UCMS+Feb) analysis of variance (ANOVA) with an interaction term, and a Tukey
post-hoc test was performed to determine differences between groups. The effects of
TEMPOL, XO, febuxostat, and L-NAME on the maximal dilation of the MCA were
examined with a repeated-measures ANOVA. Clinical characteristics between the
animals were compared with a One-Way ANOVA with Tukey post-hoc test, as
appropriate. Behavior data were analyzed with a two-way ANOVA, and a Tukey post-hoc
test was performed to determine differences between groups. Data analysis and graphing
were conducted using GraphPad Prism version 9 software (GraphPad Software, Inc.) and
p ≤ 0.05 was set for statistical significance.
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Results:
Animal Characteristics and Stress Response: At the completion of the study, no
significant differences were noted in body mass between groups. Plasma levels of
corticosterone were significantly increased in the UCMS group compared to controls
(p<0.05). Behavioral assessments revealed poorer coat status of mice undergoing UCMS
as well as an increased latency to lick and a decreased number of licks in the sucrose
splash test compared to control mice (p<0.05). With the exception of corticosterone, all
other stress behaviors remained elevated in the UCMS+Feb group compared to the
control group (Table 1).

MCA Function: The endothelium-dependent dilation (EDD) of the MCA in response to
increasing concentrations of ACh is summarized in Figure 1. Maximum EDD was 58%
lower (p<0.001) in UCMS compared to control mice (Figure 1A). This impaired EDD
response was a result of a reduced NO-mediated dilation as indicated by a smaller
reduction in EDD in the presence of the NO inhibitor L-NAME as compared to ACh
response in the absence of L-NAME (Figure 1B). The endothelial-independent response
of the MCA in response to increasing concentrations of SNP was not affected by UCMS
(Figure 2A). Similarly, the response of the MCA to PE, a potent vasoconstrictor, was also
similar and was not affected by UCMS (Figure 2B).
To explore the role of oxidant-mediated impairment of MCA function, we acutely
incubated the MCA with XO to induce a pro-oxidative environment, this XO incubation
reduced (p<0.05) maximal EDD in all groups (Figure 3A). Next, we acutely incubated the
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MCA with Tempol (a SOD mimic) or febuxostat (XO inhibitor) (Figures 3B and 3C). Both
reducers of oxidant levels were equally as effective in restoring maximal EDD of the MCA
in the UCMS group. Tempol and febuxostat incubation had no additional benefit on the
maximal MCA EDD in the control, control+Feb, or UCMS+Feb groups. Next, we
examined the effects of chronic febuxostat treatment on MCA function. Chronic
febuxostat treatment prevented the impaired EDD to ACh with UCMS by restoring NOmediated dilation (Figures 1A and 1B). There were no differences in NO-mediated EDD
among the control, control+Feb, and UCMS+Feb treated mice. Further, the MCA
response to SNP or PE was not affected by febuxostat.

MCA Wall Diameters and Stiffness: We next examined the extent to which UCMS affected
the structural phenotype of the MCA. MCA wall diameters, WT, and wall lumen ratio did
not differ between groups, and no differences were noted in myogenic tone between
groups (Table 2).

Oxidative Stress: We used immuno-spin trapping, via western blot, to assess
biomolecular free radical formation occurring under chronic stress conditions and the role
of inhibiting XO. Densitometric analysis of the total staining for the entire lane (normalized
to GAPDH), revealed 26% greater liver DMPO levels in the UCMS compared to controls
(p<0.05; Figure 4). Whereas, liver DMPO concentrations were similar between control
and UCMS+Feb groups and significantly lower compared to the UCMS group (Figure 4).
To begin to understand the source of this increased free radical formation, XOR protein
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concentrations were examined in the liver. Chronic stress increased liver XOR
concentrations by 87% (p<0.05) compared to control mice (Figure 4C), which remained
increased in the UCMS+Feb mice compared to controls. Next, we examined liver XO
activity; however, no differences were noted in liver XO activity between the control and
UCMS groups (Figure 4E). In contrast, Con+Feb and UCMS+Feb groups demonstrated
diminished liver XO activity compared to the control and UCMS groups (p<0.05, Figure
4E). As hydrogen peroxide is the main oxidant product of XO33, we used the coumarin
boronic acid (CBA) assay to measure liver hydrogen peroxide production. Liver hydrogen
peroxide production was 6-fold higher in the UCMS vs. control groups, whereas the
UCMS+Feb group had similar levels of hydrogen peroxide in the liver compared to control
mice (Figure 4F). In addition, we measured XO activity in the plasma (Figure 5) and found
a 44% increase (p<0.05) in XO activity in the UCMS compared to the control group,
whereas plasma XO activity was significantly reduced in the UCMS+Feb group compared
to the UCMS group.
Next, we explored the XO pathway in the brain. In brain homogenate, DMPO
concentrations were similar between groups (Figure 6A). We then explored XOR protein
levels and found similar concentrations of XOR between groups (Figure 6B). Similarly,
XO activity in brain homogenate was similar between groups (Figure 6C). Next, we
assessed hydrogen peroxide production within the brain homogenate and found a 5-fold
increase in hydrogen peroxide production in the UCMS group compared to controls
(p<0.05; Figure 7A). We also explored hydrogen peroxide concentrations in isolated brain
microvessels and found a 2-fold increase in hydrogen peroxide production in the UCMS
group compared to controls (p<0.05; Figure 7B). Febuxostat prevented this increase in
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hydrogen peroxide production in both the brain and isolated brain microvessels (p<0.05;
Figures 7A & 7B).

Behavior: Open field test was used as a measure of locomotive behaviors; no differences
were noted in the total number of beam breaks (Figure 8A) or the number of vertical beam
breaks (rearing) (Figure 8B) between groups. Working memory was examined using the
spontaneous alternation Y-maze, and we found that the UCMS mice were significantly
(p<0.05) impaired (18% reduction) in their ability to successfully undergo spontaneous
alternation compared to control mice (Figure 8E). However, in contrast, the UCMS+Feb
mice had a similar ability to successfully undergo spontaneous alternation compared to
the control mice. Importantly, as noted with the open field test, and now with the y-maze
test, the total distance traveled and the average speed was similar between groups
(Figure 8C and D), indicating the potential confounding impact of locomotor disruptions
on the cognitive effects was not evident.

Discussion
The current study was undertaken to examine the role of XO in mediating chronic stressinduced cerebrovascular dysfunction. To accomplish our goal, we pharmacologically
inhibited XO with febuxostat that was supplemented in the drinking water of chronically
stressed mice. Cell culture work has shown that febuxostat (25 and 50 nM) was effective
at reducing cell-bound oxidative stress production by 96 and 100%, respectively36. A
number of novel observations were made in the current study: 1) chronic stress increased
liver XOR production, and liver free radical formation including the increased production
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of H2O2, with an increase in circulating XO; 2) chronic stress increased the production of
H2O2 in brain tissue and specifically within the cerebrovasculature; 3) febuxostat
treatment during chronic stress prevented the stress-induced MCA EDD dysfunction by
maintaining NO-dependent dilation; 4), febuxostat treatment prevented the increase in
oxidative stress in the liver, brain, and cerebrovasculature, and lowered circulating XO;
and lastly 5) the memory deficits noted with chronic stress were absent in the febuxostat
treated mice. Thus, these data support the central hypothesis that XO plays an important
role in the cerebrovascular dysfunction noted with chronic stress.
A previous study, using a more extreme form of stress (restraint stress) over 2
weeks compared to our progressive set of mild stresses that gradually build to induce a
chronic stress-like phenotype over 8 weeks, increased XOR and XO activity, along with
an accumulation of oxidative stress in visceral adipose tissue, liver, and intestines, and
that treatment with febuxostat, suppressed stress-induced oxidative stress production11.
Oxidative stress is a driving force for arterial dysfunction noted with chronic stress 7,8,37,
and our past work using a rat model has shown that oxidative stress plays a key role in
the stress-induced MCA dysfunction as: 1) the oxidative load in the MCA of male UCMS
rats was 2-fold higher vs. controls7; and 2) acute inhibition of oxidative stress with tempol
rescued MCA function in male UCMS rats7. In the current study, we confirm in a mouse
model, which includes both male and female mice, that chronic stress induces
considerable cerebrovascular dysfunction alongside a pro-oxidative stress environment.
A novel aspect of our study is the identification that XO plays a critical role in stressinduced cerebrovascular dysfunction. XOR includes the XO and XDH forms of the same
enzyme. XOR is transcribed and translated from a single gene (Xdh) as XDH, which
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oxidizes hypoxanthine to xanthine to uric acid while reducing NAD+ to NADH. Under
inflammatory or hypoxia conditions, XDH is post-translationally modified to XO which
catalyzes the same purine reactions but uses oxygen as the electron acceptor to generate
superoxide (O●-2) and H2O2. The liver is one of the sites of greatest XOR activity and is
the main source of circulating XOR20,38. When released from the hepatocytes into the
circulation, XDH is rapidly converted to XO by plasma proteases and subsequently binds
with high affinity to the endothelial GAGs19, where it can induce endothelial damage. In
addition, the endothelium is also a source of XOR activity39, and we have shown XO-GAG
interaction serves to amplify the local endothelial XOR levels in vascular beds distal from
the site of origin (e.g. liver)40,41.

To assess XO as a potential source of this oxidative stress environment, control
(non-stressed mice) MCAs were incubated with XO and xanthine; these vessels
displayed impaired MCA response to ACh, similar to the MCA dysfunction noted in UCMS
mice. Further, acute incubation of the MCA from UCMS mice with febuxostat rescued
MCA EDD to ACh. In support of this, our chronic inhibition of XO with febuxostat
(supplementation in the daily drinking water) of mice exposed to chronic stress prevented
the dysfunction of the MCA. In particular, chronic febuxostat supplementation rescued the
NO-dependent dilation in the pursuit of preserving endothelial function, potentially via two
possible mechanisms. The first is that chronic stress inhibits endothelial NO synthase
activity and prevents NO from being produced. This is supported in a model of aging, in
that an inverse relationship was shown between XO expression and endothelial NO
synthase with XO being named as the main contributor to the oxidative stress within the
aorta42. It is also possible that chronic stress does not inhibit endothelial NO synthase
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activity, but instead invokes endothelial NO synthase uncoupling resulting in peroxynitrite
production and decreased NO bioavailability within the cerebrovasculature 43,44.

It is important to note that no differences were noted in smooth muscle cell function
either in the response of the MCA to SNP or the myogenic tone response. This is
confirmed in past work in which healthy animals with no other predispositions exposed to
chronic stress resulted in no smooth muscle cell dysfunction 7. However, in instances of
chronic stress predisposed with another comorbidity (i.e. obesity), smooth muscle cell
dysfunction is present, both in SNP dilation and myogenic tone7. Importantly, obesity is
associated with a substantial increase in the XO pathway20 and we have shown that with
obesity there is a substantial increase in vascular oxidative stress7. Further, inhibiting XO
with febuxostat in the context of obesity prevented the increased liver production of XO
and free radicals20. Interestingly, within the smooth muscle cells, uric acid and XO are
capable of inducing inflammation and O•-2 and peroxynitrite can blunt G protein-mediated
activity and inhibit soluble guanylyl cyclase, respectively45–47.

The precise mechanism whereby chronic stress stimulates increased oxidative
products leading to arterial dysfunction by XO is not entirely clear. XOR can increase
oxidative stress via changes in the expression or activity of the enzyme. Our data shows
that the XOR protein levels were significantly higher in the liver of UCMS mice, however,
XO activity in the liver was similar between UCMS and control mice. This increased
expression of XOR in the liver with stress coincides with an increased oxidative
environment in the liver. We used an in vivo immuno-spin trapping method for indirectly
assessing oxidant levels by detecting free radicals resulting from the reaction of oxidants
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with biomolecules to form stable, immunologically detectable nitrone-biomolecular
adducts. We found that DMPO-labeled adducts were significantly elevated in the liver of
UCMS mice compared to controls. This increased total free radical production in the liver
was further supported by a significant increase in liver H2O2 production. Often, XO is
mainly referred to as a source of O•-2 with rare mention of the XO-catalyzed H2O2
production, and it is often assumed that H2O2 formation results from either reaction of XOderived O•-2 with superoxide dismutase or spontaneous dismutation of O•-2. However, XO
is a H2O2 producing enzyme that also produces some O•-241. Chronic febuxostat treatment
with UCMS significantly reduced XO activity in the liver, however, XOR protein levels in
the liver remained high. This is not surprising given that febuxostat does not impact XOR
expression, but febuxostat does impact activity, as confirmed in our study, in both the
control+Feb and UCMS+Feb groups. In addition, we found a significant reduction in
DMPO and H2O2 levels in the liver in the UCMS mice treated with febuxostat. These data
would suggest that, in part, XO production in the liver with chronic stress is playing a
significant role in the cerebrovascular dysfunction noted with chronic stress.
Liver XOR has been implicated in the facilitation of XO to the circulation resulting
in its distribution to alternative tissue sites (like the brain vasculature), resulting in arterial
dysfunction. Indeed, UCMS increased circulating XO which was lowered when UCMS
was combined with chronic febuxostat treatments. Other sources of XOR may be equally
important. Given the proximately of the brain tissue with the cerebrovasculature we
explored XOR protein and XO activity in brain homogenate. No differences were noted in
XOR protein or XO activity in the brain. However, H2O2 was significantly increased in the
brain tissue of UCMS mice, and significantly reduced in the UCMS+Feb treated mice.
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Other studies have found that XOR expression and activity in brains were low compared
to the liver48 but the Xdh expression was upregulated with global brain ischemic
reperfusion injury49. These data would suggest that the distribution of XOR in the brain is
low, and perhaps not the source of XOR. However, further investigation is needed with
genetic XOR knockout models. Importantly, we found that the production of H2O2 was 2fold higher in the cerebrovasculature of UCMS compared to control mice, and that chronic
febuxostat treatment with UCMS significantly reduced H2O2 production specifically in the
cerebrovasculature. We were unable to measure total free radical production (using
DMPO) in the cerebrovasculature due to low levels of protein. These data, along with the
protection of the cerebrovascular function with chronic febuxostat treatment (ex vivo MCA
data), would suggest that XO is playing a significant role in the cerebrovasculature.
Indeed, the endothelial cells are an alternative source of XO, which may be responsible
for the cerebrovascular dysfunction noted with stress and its protection with chronic
febuxostat treatment. The presence and activity of XOR in endothelial cells have been
noted by numerous studies50,51. Cultured endothelial cells exposed to hypoxia resulted in
increased expression elevated protein abundance and enhanced enzymatic activity and
extracellular release of XO52. Further, in humans, the levels of endothelial-bound XO
correlate with the presence of coronary artery disease and are inversely proportional to
flow-mediated brachial artery vasodilatation39. This XO-GAG association induces
substantial sequestration and thus amplification of local endothelial XO concentration,
producing a microenvironment primed for enhanced oxidative stress (i.e., a further shift
in oxidant formation from O2•− to H2O2)39. Thus, we have an environment in which
circulating XO can bind to the GAG on the endothelial cells (GAG-bound) to upregulate
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ROS generation, and this is further compounded by the local XO production from the
endothelium (i.e., endothelial cell-bound XO). This deleterious action of XO has been
noted in various reports of arterial and cardiopulmonary diseases including heart failure,
pulmonary hypertension, sickle cell disease, and diabetes53–56.
The potential clinical consequences of chronic stress on brain health are evident
in the reduction in working memory in chronically stressed mice, as assessed by the ymaze test. These data suggesting that chronic stressful events can lead to cognitive
decline are supported in both human57,58, and animal models59,60. Epidemiological data
indicate that stressed individuals are more likely to develop mild cognitive impairment, or
even dementia, compared to non-stressed individuals61,62. Working memory is perhaps
one of the most well-modeled aspects of the cognitive deficits in Alzheimer’s Disease63,
and the Y-maze type tasks, which require spatial working memory to solve, are one of the
most widely used paradigms for working memory in mice. Epidemiological64–68, and preclinical studies69–71 support the idea that arterial alterations are early events in cognitive
deficits and one of the strongest brain pathology associated with Alzheimer’s Disease. As
such, the cerebrovascular dysfunction noted with chronic stress, coupled with the
increased oxidative environment in the brain and cerebrovasculature is a possible
mechanistic pathway linking chronic stress and cognitive decline. Indeed, we show that
blocking XO with febuxostat not only protected the cerebrovascular function but also
prevented the decline in working memory that was noted with chronic stress. The
relationship between chronic stress and cognitive decline is particularly important for the
health of older adults who are at greater risk for developing dementia. There is a known
link between age-associated oxidative stress leading to cerebrovascular dysfunction and
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cognitive decline68,72. And along the lines of the two-hit vascular hypothesis of Alzheimer's
Disease, the compromised health of the cerebrovasculature with chronic stress, maybe
an initial insult that is sufficient to initiate neural injury and neurodegeneration and
promote

the

accumulation

of

amyloid

β-peptide and

tau

accumulation

and

phosphorylation. In fact, animal studies have shown a link between stress and
neuropathology associated with dementia, demonstrating that stress is associated with
synapse loss73, increases in amyloid β-peptide74,75, and tau accumulation and
phosphorylation75,76.
Conclusions
The present study demonstrates the role of XO in chronic stress-induced cerebrovascular
dysfunction. We show that chronic stress increased liver XO production as well as
increased free radical formation within the liver, brain, and cerebrovasculature. Chronic
febuxostat supplementation prevented the stress-induced MCA dysfunction, prevented
the stress-induced pro-oxidative stress environment within the liver, brain, and
cerebrovasculature, and prevented stress-induced deficits in working memory. Taken
together, these data support the role of XO in chronic stress-induced cerebrovascular
dysfunction.
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Figure Legends
Figure 1: Endothelial-dependent and nitric oxide (NO)-dependent dilation. (A) Dose
response to the endothelial-dependent dilator acetylcholine (ACh) and (B) MCA maximal
NO-dependent dilation = (Max DilationACh) - (Max DilationACh+L-NAME), in control and UCMS
mice with (+Feb) or without chronic Febuxostat treatment. * p<0.05 vs control; ^p<0.05
vs control+Feb; +p<0.05 vs UCMS+Feb; mean±SD. n=16-20/group. Repeated measured
ANOVA (with tukey post-hoc test).

Figure 2: Endothelial-independent dilator and constrictor response. (A) Dose-responses
of the MCA to the endothelial-independent dilator sodium nitroprusside (SNP), and (B)
the vasoconstrictor response to Phenylephrine (PE) in control, and UCMS mice with
(+Feb) or without chronic Febuxostat treatment. *p<0.05 vs control; ^p<0.05 v
control+Feb; +p<0.05 vs UCMS+Feb; mean±SD. n=17-20/group. Repeated measures
ANOVA (with tukey post-hoc test).

Figure 3: Maximal endothelial-dependent response and the role of oxidative stress.
Maximal dose-responses to the endothelial-dependent dilator acetylcholine (ACh), during
acute (30 min) incubation with xanthine oxidase (A), Tempol (B), and Febuxostat (C). #
p<0.05 vs no incubation experiment within same group; mean±SD; n=16-20/group.
Repeated measures ANOVA (with tukey post-hoc test).

Figure 4: Oxidative stress in the liver. (A) 5,5-Dimethyl-1-Pyrroline-N-Oxide (DMPO) was
used to detect free radical formation on biomolecules in the liver via western blotting; (B)
quantification of DMPO western blot. (C) Xanthine oxidase reductase (XOR)
concentration was assessed within the liver using western blotting techniques. (D)
71

representative XOR western blot image. (E) Liver XO activity measured with HPLC. (F)
The CBA assay was used to assess hydrogen peroxide production within the liver.
*p<0.05 vs control; ^p<0.05 vs control+Feb; ‡p<0.05 vs. UCMS; +p<0.05 vs UCMS+Feb;
mean±SD. n=4-17/group. One-way ANOVA with tukey post-hoc test

Figure 5: Plasma XO activity. Plasma XO activity measured with HPLC.* p<0.05 vs
control; ^p<0.05 vs control+Feb; +p<0.05 vs UCMS+Feb; mean±SD. n=12-23/group.
One-way ANOVA with tukey post-hoc test.

Figure 6: Oxidative stress in the brain. (A) 5,5-Dimethyl-1-Pyrroline-N-Oxide (DMPO)
was used to detect free radical formation on biomolecules in the brain via western blotting;
(B) quantification of DMPO western blot. (C) Xanthine oxidase reductase (XOR)
concentration was assessed within the brain using western blotting techniques. (D)
representative XOR western blot image. (E) Brain XO activity measured with HPLC.
*p<0.05 vs control; ^p<0.05 vs control+Feb; ‡p<0.05 vs. UCMS; +p<0.05 vs UCMS+Feb;
mean±SD. n=4-14/group. One-way ANOVA with tukey post-hoc test

Figure 7: Oxidative stress within the brain and isolated brain microvessels. The CBA
assay was used to assess hydrogen peroxide production within (A) whole brain
homogenate and (B) isolated brain microvessels. *p<0.05 vs control; ^p<0.05 vs
control+Feb; +p<0.05 vs UCMS+Feb; mean±SD. n=6-9/group. One-way ANOVA with
tukey post-hoc test.
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Figure 8: Locomotor and cognitive behavior with chronic stress. Open field test was used
to measure locomotor behavior with total horizontal movements via beam breaks (fine
and ambulatory combined) in the arena (A), and the number of vertical beam breaks
(rearing; B). Spontaneous alternation Y-maze test was used to measure locomotor
behavior (distance moved [C] and speed [D]) and working memory (E). mean±SD. n=1118/group. One-way ANOVA with tukey post-hoc test. * p<0.05 vs control; ^p<0.05 vs
control+Feb.
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Table 1: Animal Characteristics
Control
UCMS
Control+Feb
UCMS+Feb
Males (%)
50%
53%
56%
53%
Body Mass, g
26.5±4.2
24.8±3.6
25.7±3.5
26.2±3.7
Mean Blood Pressure, mmHg
122±11
127±11
118±12
129±9
Corticosterone, ng/ml
112.5±74.9
227.0±126.4* 150.0±102.1
142.2±67.7
Coat Scores, AU
0.5±1.2
6.3±1.3*
0.9±1.4
5.7±1.8*
Sucrose Splash-Latency
7.3±7.2
20.5±16.5*
9.0±8.0
24.3±27.5*
(sec)
Sucrose Splash-Number of
41.9±20.7
27.5±17.5*
40.8±17.3
25.1±19.4*
Licks
Mean±SD. p*<0.05 vs. Con; n= 22-28/group except corticosterone n=11-12/group

Table 2. Active and passive middle cerebral artery responses

Control

UCMS

Active OD (µm)
95±16
98±15
Myogenic Tone
36±10
27±11
(%)
Passive
ID (µm)
93±10
90±11
OD (µm)
121±14
117±12
WT (µm)
14±3
14±3
WLR
0.30±0.07
0.31±0.08
Pressure=60mmHg; Mean±SD, n=15-20/group.

Control+Feb

UCMS+Feb

91±18
40±11

89±14
37±12

92±11
121±12
14±4
0.32±0.09

91±15
119±16
14±4
0.31±0.12

OD= Outer Diameter
ID= Inner Diameter
WT= Wall Thickness
WLR= Wall to Lumen Ratio
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Abstract

Background: The aim of this study was to assess the impact of sodium nitrite
supplementation on chronic stress-induced cerebrovascular dysfunction. We hypothesize
that nitrite supplementation will prevent the oxidative environment and cerebrovascular
dysfunction associated with chronic stress.
Methods and Results: 18-week-old male/female C57BL/6 mice underwent 8 weeks of
control conditions or unpredictable chronic mild stress (UCMS) with or without sodium
nitrite (50mg/L) in the drinking water. Excised middle cerebral arteries (MCA) were
mounted in a pressurize myobath and exposed to increasing concentrations of
acetylcholine (ACh). Nitrite supplementation prevented the UCMS-induced impaired ACh
response in the MCA. We examined biomolecular free radical formation, via immuno-spin
trapping with DMPO, xanthine oxidoreductase (XOR) protein abundance, and hydrogen
peroxide production in the liver and brain. Nitrite supplementation prevented the
development of an oxidative environment within the liver, brain, and cerebrovasculature.
Assessment of working memory revealed that sodium nitrite did not fully prevent the
impairment of cognitive function as a result of chronic stress.
Conclusion: These data suggest that it is possible to manipulate the xanthine oxidase
pathway with nitrite supplementation to prevent cerebrovascular dysfunction, but it is not
sufficient to prevent cognitive impairment with chronic stress.
Key Words: Sodium Nitrite, UCMS, Middle Cerebral Arterty, oxidative stress, cognition
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Introduction
Chronic stress, defined as a state of threatened homeostasis in response to various
stimuli1 has serious health and social consequences with more than 77% of adults
reporting significant sources of stress in their lives2. Chronic stress is a powerful risk factor
in developing various cerebrovascular diseases which are the leading cause of long-term
disability as well as the second leading cause of death worldwide 3. We have shown in
various pre-clinical models that chronic stress substantially blunts (~50%) endothelialdependent dilation (EDD) in the middle cerebral artery (MCA) via reduced nitric oxide
(NO) bioavailability4–6. The decline in MCA function is critical as it is the main blood
vessel that brings oxygen and nutrients to the brain, supplying ≈50% of the cerebral blood
flow7.
Oxidative stress is a driving force for cerebrovascular dysfunction4,8,9. We have
shown that after 8 weeks of chronic stress the oxidative load in the brain and
cerebrovessels was increased 2-5-fold and that acute inhibition of oxidative stress with
tempol (a free radical scavenger) or febuxostat (inhibitor of xanthine oxidase) rescued
MCA function4,6. Further, we have shown that xanthine oxidase (XO) protein abundance
is increased in the liver, with an increase in plasma XO activity of chronically stressed
mice6. XO is a variant of xanthine oxidoreductase (XOR) and an abundant source of
hydrogen peroxide (H2O2) and superoxides (O2●−) and under hypoxic and proinflammatory conditions that can reduce NO directly with O2●− (forming peroxynitrite), or
indirectly by mediating redox-dependent cell signaling reactions thereby affecting
endothelial cell function10,11. The liver is a major site of XOR and the main source of
circulating XOR12,13. When released from the hepatocytes into the circulation, XDH is
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rapidly converted to XO by plasma proteases and subsequently binds with high affinity to
the endothelial glycosaminoglycans (GAGs)14, where it can induce endothelium damage.
In addition, the endothelium is a source of XOR activity15, and we have shown XO-GAG
interaction serves to amplify the local endothelial XOR levels in vascular beds distal from
the site of origin16,17. Further, inhibiting XO can completely prevent the MCA dysfunction,
and lowered the oxidative load in the brain and cerebrovasculature of chronically stressed
mice6. These data highlight the importance of the XO pathway on the stress-induced
cerebrovascular dysfunction.
NO is a small, diatomic gaseous signaling molecule and continuous NO generation
is essential for the regulation of an array of physiological functions essential for
maintaining neurological, and cardiovascular health. Interestingly, XO is also considered
to be the primary endogenous pathway to catalyze the reduction of nitrite (NO2-) to NO18–
21.

Serial reductions of nitrate and NO2-, through enzymatic systems, can lead to the

formation of NO that can influence vascular function. Several studies have shown that
many of the favorable cardiovascular actions that have been coupled with NO 2- treatment
are attenuated or even abolished by simultaneous treatment with XO inhibitors18,22,23. The
goal of this study is to exploit the fact that XO is elevated with chronic stress and switch
XO product formation from H2O2 and O2●- to NO. That is, using NO2- to switch XO from
being associated with “bad” outcomes to a potential source of “good” or protective
processes. We hypothesize that chronic supplementation of NO2- during the chronic
stress model will increase NO bioavailability, reduce oxidative stress, and prevent the
MCA endothelial dysfunction with chronic stress.
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Methods
Animals and group allocation: Male and female C57BL/6J (Jackson Laboratory) arrived
at the West Virginia University Health Sciences Center (WVUHSC) animal facility at 7-8
weeks of age. After 1 week of acclimation to the local environment, mice were randomly
assigned to a specific protocol group for the subsequent 8 weeks including 1) control
(non-UCMS), 2) UCMS, 3) control and nitrite (Con+NO2-), and 4) UCMS and nitrite
(UCMS+NO2-). All animals were fed standard chow and tap water ad libitum for all
experiments. Protocols received prior approval from the WVUHSC Animal Care and Use
Committee.

Nitrite treatment: Vehicle (standard drinking water) or NNaO2 (Fisher scientific, PA, USA)
was delivered daily in the drinking water at a concentration of 50mg/L. The water was
measured frequently to calculate the concentration of NO2- consumed daily (∼5–6 mg/kg
per day).

Chronic Stress Intervention: As previously performed (Burrage 2022), we used the
Unpredictable Chronic Mild Stress (UCMS) model to induce chronic stress in our mice.
Every single stressor (damp bed, cage tilt, cage reversal, etc) is of minor concern similar
to humans with one bad day among many average days. But with multiple stressors over
8 weeks rodents cannot adapt, resulting in an increase in stress hormones and limited
grooming. This is similar to a human facing a wide variety of unpredictable hassles across
many bad days.
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All mice were singly housed. In UCMS groups, mice were exposed to the following mild
environmental stressors in randomly chosen sequences for ~7 hours each day, 5
days/week, over the course of 8 weeks:
1. Damp bedding – 10 oz. of water was added to each standard cage
2. Bath – all bedding was removed and ~0.5 inches of water was added to empty
cage. Water temperature was room temperature, ~24°C
3. Cage Tilt - cage was tilted to 45 degrees without bedding
4. Social stress – each mouse was switched into a cage of a neighboring mouse
5. No bedding – all bedding was removed from the cage
6. Alteration of light/dark cycles –turning lights off/on in random increments for a
scheduled period.

Stress markers: At the time of death, plasma was collected and using a commercially
available corticosterone ELISA kit (Arbor Assay, Item #K014), corticosterone levels were
examined in triplicate according to the manufacturer's instructions. During the duration of
the 8-week protocol, the rodent’s coats were evaluated. Each week the mice were
inspected for grooming habits24 and the total cumulative coat score was computed by
giving an individual score of 0 (clean) or 1 (dirty) to eight different body parts (i.e. head,
neck, back, forelimbs, stomach, hindlimbs, tail, genitals). Following the 8-week protocol,
sucrose splash testing was performed to assess grooming behavior. The sucrose splash
test consisted of spraying a 10% sucrose solution on the dorsal coat of a mouse in an
empty cage; latency to begin grooming as well as frequency were recorded for a total of
5 minutes25.
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Behavior
Y-maze spontaneous alternation: To assess short-term working memory, following a 30minute room acclimation period, under indirect dim illumination conditions (approximately
150 lx), mice were placed in the three-armed, Y-shaped apparatus (approximate arm
length = 38 cm, width = 8.25 cm, height = 13.25 cm) and allowed to freely explore for 8
min. Movement in the apparatus was recorded using the Anymaze tracking software
(Stoelting, Chicago, IL). The innate tendency of mice to spontaneously alternate between
the three arms and enter the least recently visited arm was assessed by determining the
percentage of successful alternations ((number of correct alternations/(total arm entries
− 2)*100). Other dependent variables recorded included distance moved (m) and speed
(m/s). Between each animal, each apparatus was cleaned of debris and olfactory cues
using an anti-bacterial disinfectant (Virkon, Pharmacol, CT).

Open field test: This task evaluates locomotor activity and emotional reactivity 26. Total
movement in the arena indicates general locomotor ability and movement in the center
vs periphery indicates anxiety status. The apparatus consisted of a clear plastic box (40
cm × 40 cm) surrounded by a 16 × 16 laser beam array (San Diego Instruments, CA) that
allowed for the assessment of movement in the horizontal axis. A second array placed
3.8 cm above the first beam allowed for the assessment of locomotion in the vertical axis
(rearing behavior). Following a 30-minute acclimation to the testing room (approximately
1500 lx), each subject was placed in the center point of the arena and allowed to freely
explore for 30 min. To assess treatment-induced alterations in anxiety-like behavior, the
open field arena was divided into a central square zone (approximately 700 cm2) and a
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peripheral frame (approximately 940 cm2) zone and horizontal locomotion was assessed
in each zone (peripheral and central). Thus, dependent variables were the number of total
horizontal movements via beam breaks in the arena as well as in the peripheral and
central zones, and the number of vertical beam breaks (rearing).

Vascular reactivity/mechanics: Mice were euthanized and the brain was carefully
removed from the skull and placed in a cold physiological salt solution (PSS; 4ºC). Both
middle cerebral arteries (MCA) were dissected from their origin at the Circle of Willis and
placed into an isolated microvessel chamber (living systems) filled with PSS. Each MCA
was subsequently doubly cannulated within a heated chamber (37°C) that allowed the
lumen and exterior of the vessel to be perfused and superfused, respectively, with PSS
from separate reservoirs. The PSS was equilibrated with a 21% O 2, 5% CO2, and 74%
N2 gas mixture and had the following composition (mM): 119 NaCl, 4.7 KCl, 1.17 MgSO4,
1.6 CaCl2, 1.18 NaH2PO4, 24 NaHCO3, 0.026 EDTA, and 5.5 glucose. Any side branches
were ligated. MCA diameter was measured using television microscopy and an on-screen
video micrometer.

Measurements of Vascular Reactivity in Isolated MCA: Following cannulation, MCAs
were extended to their in-situ length and were equilibrated at 70 mmHg mean arterial
pressure. Active tone at the equilibration pressure was calculated as (ΔD/Dmax) × 100,
where ΔD is the diameter increase from rest in response to Ca2+-free PSS, and Dmax is
the maximum diameter measured at the equilibration pressure in Ca 2+-free PSS.
Following equilibration, the MCA dilator reactivity was assessed in response to increasing
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concentrations of an endothelial-dependent dilator (EDD, acetylcholine; ACh, 10−9M –
10−4M), endothelial-independent dilator (EID, sodium nitroprusside; SNP 10−9M – 10−4M),
and a potent vasoconstrictor (phenylephrine, PE 10 −9M – 10−4M). To assess the effects
of NO on EDD, the MCA was acutely incubated (30 minutes) with L-NAME (10−4 M) and
the MCA EDD response to ACh was repeated. To assess the acute effects of oxidative
stress on modulating EDD, we acutely (30 minutes) incubate the MCA with 1) TEMPOL
(10−4M, Sigma Aldrich, cat# 176141); and 2) febuxostat (10mM; Axon Medchem BV,
Netherlands). Following completion of all procedures, the perfusate and superfusate were
replaced with Ca2+-free PSS and the passive diameter of the fully relaxed MCA was
determined over an intralumenal pressure range of 5–140 mmHg at 20-mmHg pressure
increments. After 7 min at each intraluminal pressure, the inner and outer diameters of
the passive MCA were determined. Media thickness, lumen and outer diameters, and
vessel cross-sectional areas (used as indicators of structural alterations to the individual
microvessel) were determined as follows: Media thickness (WT, μm) = Outer diameter –
lumen diameter (i.e., OD – LD); media-to-lumen (M:L) ratio = MT/LD; Cross-sectional
area (μm2) = Outer vessel area – lumen area. Myogenic tone was assessed using the
following formula: 1-(active diameter/passive diameter)*100 (Rigsby, 2007). NOdependent dilation was determined from the maximal EDD in the absence or presence of
L-NAME according to the following formula: NO-dependent dilation (µm) = Maximum
dilationACh - Maximum dilationACh+L-NAME.

Cerebral Microvessel Isolation: To explore the vascular signaling pathway, the mouse
brain was carefully removed, the MCA was dissected for pressure-myography, and then
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the remaining cerebral microvessels (parenchymal and meninges vessels) were isolated
from the brain using dextran centrifugation method. In brief, brain tissue was
homogenized in 1X PBS and centrifuged 2960 rpm at 4°C. The supernatant, containing
parenchymal tissue was discarded; the pellet was resuspended and layered over 15%
Dextran (in 1X PBS) (Sigma Aldrich, Item #31390). Following 30-minute centrifugation at
4000rpm at 4°C, the supernatant was discarded, and the pellet was resuspended in 1%
bovine serum albumin (BSA) in 1X PBS. The suspension was then passed through a
70um cell strainer with the microvessels being collected on the mesh. The microvessels
were then washed with 1% BSA in 1X PBS and collected by centrifugation at 3000 rpm
for 10 min at 4°C. Following this, microvessels were rinsed with 1X PBS, centrifugated at
4000 rpm for 5 min at 4°C and flash frozen for future use in other assays (adapted from
Austin).

Tissue Oxidants: As briefly described below, the brain, liver, and microvessels were
explored for oxidative products.
Xanthine Oxidase-HPLC: XO activity was measured in the plasma, liver, and brain tissue
as previously described using high-performance liquid chromatography (HPLC)12,27.
Samples were homogenized in ice-cold RIPA containing a protease inhibitor cocktail
(Sigma) and spun down. Tissue samples were processed as described below with a
sample volume of 10µL. Uricase was inhibited by oxonic acid (100 µM) to avoid an
underestimation of enzyme activity. Total XOR activity was determined on the basis of
the rate of uric acid production in the presence of xanthine (75 µM) and nicotinamide
adenine dinucleotide (NAD+, 0.5 mM). Allopurinol (100 µM), an inhibitor of XOR, was
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used in parallel samples to confirm that urate formation was specific. After 60 min of
incubation at 37°C, the reaction was terminated by protein precipitation with cold
acetonitrile. The samples were then centrifuged for 12 min at 13,200 x g, at 4°C. Following
centrifugation, the supernatant was removed and placed in borosilicate glass tubes. After
a 60-minute dry-down process, the samples were resuspended in isocratic mobile phase
(300 µL) and filtered through a 0.20 µm nylon membrane filter unit into 11 mm plastic
snap-top auto-sampler vials. The uric acid content of protein-free samples was
determined by an HPLC-based electrochemical technique as described below. One unit
of activity (U) is defined as 1 µmole/min urate formed at 37°C and pH 7.4. Total protein
concentration was determined by the bicinchoninic acid method (BCA, Pierce).
Measurements were carried out blindly without knowledge by the operator of the animal
treatment groups. Uric acid was measured by electrochemical detection (Vanquish
UltiMate 3000 ECD-3000RS) coupled to reverse-phase HPLC using a Phenomenex
column (Luna 3µm C18(2) 100 A, 150x4.6 mm) and isocratic mobile phase (50 mM
sodium dihydrogen phosphate, 4 mM dodecyltrimethylammonium chloride, 2.5%
methanol, pH 7.0). Potentials for 3 channels were as follows: -100mV, 30mV, and 390mV.
Quantitation/integration was performed on the dominant peak. In the case of XO activity
in plasma, 10-20 µL of plasma was used in lieu of tissue and processed with the same
protocol as above without gel filtration. XO activity in plasma utilized volume (U/mL) as a
denominator rather than protein.

Xanthine Oxidase-Western Blots: Liver and brain tissue were homogenized in 1X
PBS plus HALT inhibitor and then centrifuged at 3000 rpm at 4 °C for 20 min. An equal
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amount of protein for each sample was loaded into a polyacrylamide gel. After the
completion of gel electrophoresis, the protein was transferred to nitrocellulose
membranes overnight. XO expression was assessed using a XO antibody (1:500; Santa
Cruz; cat # sc-398548) followed by a secondary antibody (1:10,000; Licor; cat # 92532201 and 925-68071). GAPDH (1:1000; Cell Signaling; cat #2118) was used as a
loading control. Blots were imaged using Licor Odyssey and band intensity was assessed
using ImageJ software.

Coumarin Boronic Acid (CBA) Assay: Hydrogen peroxide (H2O2) abundance was
measured in homogenate from the liver, brain, and brain microvessel using the CBA
(Cayman #14051) assay as previously described28. In brief, 10μg of lysates were loaded,
in triplicate, into wells of a 384-well black-sided clear bottom plate. Subsequently, assay
buffer composed of HBSS supplemented with 25 mM HEPES, 1% BSA, 10uM DTPA,
100uM l-NAME, 1 mM Taurine was added and then CBA was added to each well at a
final concentration of 0.5 mM. One well from each biological sample received an
additional 1 KU/ml bovine liver catalase to act as a negative control. Upon addition of the
CBA, plates were placed in a Biotek plate reader preheated to 37°C and read kinetically
at excitation 350 nm and emission 450 nm. The average rate of fluorescence was
determined over the linear portion of the response and then normalized by subtracting
out the rate of fluorescence from the negative control.
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In Vivo Immuno-Spin Trapping: In a separate set of mice (3/sex/group) received
an i.p injection of 5,5-Dimethyl-1-Pyrroline-N-Oxide (DMPO: 1.5g/kg) in 3x0.5 g/kg doses
at 24, 12, 6 hours prior to sacrifice, as previously reported 29,30. Upon euthanization,
organs/tissues were perfused with phosphate-buffered saline (PBS; pH 7.4), removed,
frozen in liquid N2, and stored at −80°C for Western blot analysis. Liver and brain tissue
were homogenized in RIPA buffer plus HALT inhibitor and then centrifuged at 3000 rpm
at 4 °C for 20 min to remove insoluble materials. Equal amounts of protein for each
sample were loaded into a polyacrylamide gel. After the completion of gel electrophoresis,
the protein was transferred to nitrocellulose membranes overnight. DMPO-adducted
proteins were assessed using mouse anti-DMPO (1:500, Enzo Life Science, Item #ALX803-340) followed by a secondary antibody (1:10,000; Licor; cat # 925-32201 and 92568071). GAPDH (1:1000; Cell Signaling; cat #2118) was used as a loading control. Blots
were imaged using Licor Odyssey and band intensity was assessed using ImageJ
software.

Assessment of NO Production: NO was determined by the accumulation of nitrite (NO 2−),
the stable oxidation product of NO, in aqueous medium. NO was detected by
chemiluminescence following the reduction of NO2− with KI and CuSO4, according to
manufacturer’s instructions (Sievers)31,32. Plasma was washed twice with HBSS at 37°C
prior to incubation with 0.75 ml of HBSS containing 25 μM L-arginine plus the addition of
NO2-FA, native FAs, or vehicle (MeOH) for 5–120 min. Following treatment, the HBSS
plus treatment was collected from each well and centrifuged at 1,000 × g for 10 min. The
resulting supernatant was then injected (50 μl via Hamilton syringe) into the Sievers nitric
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oxide analyzer (NOA). Each treatment was performed in triplicate and normalized to
protein content. A serial dilution of nitrite standards was prepared for each experiment
using a freshly prepared NaNO2 solution. Background levels of NO2− concentrations were
determined using samples of dH2O and HBSS containing L-arginine.

Statistics: Data are presented as mean ± SD, unless otherwise stated. Normality was
evaluated by the Kolmogorov–Smirnov test, and outliers were identified using ROUT
analysis with a Q=1% and excluded from data presentation. As no statistical differences
were noted between male and female mice for all variables, male and female data were
combined for statistical approaches. The MCA maximal reactivity or the MCA remodeling
was analyzed by a multifactorial (experimental condition i.e., Control, UCMS, Con+ NO2, and UCMS+ NO2-) analysis of variance (ANOVA) with an interaction term, and a Tukey
post-hoc test was performed to determine differences between groups. The effects of
TEMPOL, Febuxostat, and L-NAME on the maximal dilation of the MCA were examined
with a repeated-measures ANOVA. Clinical characteristics between the animals were
compared with a One-Way ANOVA with Tukey post-hoc test, as appropriate. Data
analysis and graphing were conducted using GraphPad Prism version 9 software
(GraphPad Software, Inc.) and p ≤ 0.05 was set for statistical significance.

Results:

Animal Characteristics and Stress Response: At the completion of the study, the only
statistically significant difference in body mass was between UCMS and Control+NO296

groups (Table 1). Plasma levels of corticosterone were significantly increased in the
UCMS compared to the control and control+NO2- groups (p<0.05). The plasma
corticosterone levels did not reach statistical significance between UCMS and
UCMS+NO2- groups (p=0.0598). Behavioral assessments revealed poorer coat status of
mice undergoing UCMS as well as an increased latency to lick and decreased number of
licks in the sucrose splash test compared to control mice (p<0.05). With the exception of
corticosterone, all other stress behaviors remained elevated in the UCMS+NO2- group
compared to the control group. Plasma levels of nitrate/nitrite were significantly increased
in the UCMS+NO2- compared to the UCMS group, however, statistical significance was
not obtained when comparing the UCMS+NO2- vs. Con+NO2- group (p=0.059).

MCA Function and wall mechanics
The endothelial-dependent dilator (EDD) responses of the MCA in response to increasing
concentrations of ACh are summarized in Fig 1. An impaired EDD response to ACh was
evident early on (p<0.05, ACh 10-9M) and progressively got worse resulting in a 60%
lower (p<0.001) maximum EDD (ACh 10-4M) in UCMS compared to controls mice (Fig
1A.). This impaired EDD response was a result of a 74% smaller NO dilatory influence,
as indicated by a smaller reduction in EDD in the presence vs. absence of the NO inhibitor
L-NAME (p<0.001; Fig. 1B). The endothelial-independent dilation (EID) to SNP and the
constrictor response to phenylephrine (PE) did not differ among groups (Fig 2A and 2B).
Chronic NO2- treatment prevented the impairment in EDD to ACh with UCMS by restoring
NO-mediated dilation (Fig 1A and B). There were no differences in NO-mediated EDD
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among the Control, Control+NO2-, and UCMS-NO2--treated mice. Further, chronic NO2treatment did not affect the EID or the constrictor response of the MCA (Fig 2A and 2B).
MCA Wall Diameters and Stiffness: We next examined the extent to which UCMS affected
the structural phenotype of the MCA. MCA wall diameters, WT, and wall-to-lumen ratio
did not differ between groups, and no differences were noted in myogenic tone between
groups (Table 2).

Oxidative stress
To explore the role of oxidative stress on EDD we acutely incubated the MCA with
febuxostat (XO inhibitor) (Fig 3). The acute incubation of the MCA with febuxostat
completely restored EDD in the UCMS group (p<0.01) with no significant effect in the
control, Control+NO2-, or UCMS+NO2- groups. Next, we used immuno-spin trapping to
assess biomolecular free radical formation, via western blot, occurring under chronic
stress conditions and the role of NO2-. Densitometric analysis of the total staining for the
entire lane normalized to GAPDH revealed a 26% greater liver DMPO concentration in
the UCMS vs. control mice (p<0.05; Figure 4). Whereas liver DMPO concentrations were
similar between control and UCMS+NO2- groups, and between control+NO2- and
UCMS+NO2- groups (Figure 4). Next, we explored XOR protein abundance in the liver,
which was increased in the UCMS group (p<0.05) compared to control mice (Figure 4C),
however, the chronic treatment with NO2- prevented the increase in liver XOR protein
abundance with UCMS. Next, we examined liver XO activity, however, no differences
were noted between groups (Figure 4E). As hydrogen peroxide is one of the main end
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products of the XO pathway, we used the CBA assay to measure liver hydrogen peroxide
production. Liver hydrogen peroxide levels were significantly increased (p<0.05) in the
UCMS vs. control groups, and also compared to the Con+NO2- and UCMS+NO2- groups
(Figure 4F). Finally, we explored XO activity in the plasma and found a significant increase
in the UCMS group (p<0.05) compared to control mice (Fig 5), however, no differences
were noted between UCMS+NO2- and the control, and Con+NO2- groups.
Next, we explored the XO pathway in the brain. In brain homogenate, DMPO
concentrations (Figure 6A), XOR protein levels (Figure 6B), and XO activity (Figure 6E)
were similar between groups. However, we did note a 5-fold increase in hydrogen
peroxide production in the UCMS group compared to controls (p<0.05; Figure 7A), which
was significantly reduced in the UCMS+NO2- group (Figure 7A). Next, we explored
hydrogen peroxide production concentrations in isolated brain microvessels and found a
2-fold increase hydrogen peroxide production in the UCMS group compared to controls
(p<0.05; Figure 7B), while treatment with NO2- prevented this increase in hydrogen
peroxide production (p<0.05; Figure 7B).

Behavior: No differences were noted in the total number of beam breaks (Fig 8A) or the
number of vertical beam breaks (rearing) (Fig 8B) between groups in the open field test.
We also explored working memory using the spontaneous alternation Y-maze test and
noted a significant reduction in working memory in the UCMS and UCMS+NO2 groups
compared to controls (Fig 8E). As noted with the open field test, and now with the y-maze
test, the total distance traveled, and the average speed was similar between groups (Fig
8C and D).
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Discussion

The current study aimed to exploit the upregulation of xanthine oxidase activity
associated with chronic stress by flooding the system with nitrite 6; based on previous
evidence18,33, we hypothesized that this exploitation would result in a switch in byproducts
of xanthine oxidase activity from H2O2 and O2●- to NO, improving the cerebrovascular
dysfunction typically associated with chronic stress first by diminishing the pro-oxidative
environment and second by flooding the system with NO. To accomplish our goal, we
supplemented the water of mice undergoing chronic stress with 50mg/L sodium nitrite, a
dose that has been previously used and shown to be successful in increasing NO levels34–
36

and we were successful at increasing plasma nitrate/nitrite levels in UCMS group that

received nitrite supplementation (indicative of increased NO levels). A number of novel
observations were made in this study: (1) nitrite supplementation during chronic stress
prevented the stress-induced MCA EDD dysfunction by maintaining NO-dependent
dilation; (2) nitrite supplementation prevented the increase in oxidative stress in the liver,
brain, and cerebrovasculature; (3) and lastly the memory deficits noted with chronic stress
were not ameliorated with nitrite supplementation.
Mice receiving nitrite supplementation while undergoing chronic stress had a
typical MCA EDD response as compared to controls, primarily driven by rescued NOdependent dilation. Firstly, nitrite supplementation prevented the formation of an oxidative
environment by switching the by-products of xanthine oxidase away from H2O2 and O2●-,
limiting oxidative impairment of eNOS37–39. Secondly, nitrite supplementation provided
abundant NO availability through the enzymatic conversion of nitrite to NO. Of note, nitrite
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is rapidly absorbed from the circulation by peripheral tissues where it can be stored in
cells until it is needed for use, therefore there is a limited risk of excess NO40.
Interestingly, incubation of the MCA with febuxostat did not impact maximal EDD
response to ACh in the chronic stress groups supplemented with nitrite. Others have
shown that inhibition with febuxostat prevents the conversion of nitrite to NO by XO which
would prevent the abundant NO bioavailability18,22. However, supplementation with nitrite,
which shifted the by-product formation of XO, prevented the induction of an oxidative
environment associated with chronic stress, meaning EDD was not disrupted and the
MCA was able to produce sufficient dilation in response to ACh.
It is important to note that no differences were noted in smooth muscle cell function
either in response of the MCA to SNP or the myogenic tone response. This is consistent
with the work of both Sindler et.al.35, and Rossman et.al.36, who showed no effect of nitrite
supplementation on endothelial-independent dilation in the carotid artery of young or old
mice. However, in a mouse model of hypertension, increased matrix metalloproteinases
are seen within the smooth muscle cell and supplementation with nitrite prevents this
increase in matrix metalloproteinases41. This suggests that nitrite supplementation may
have a positive impact on smooth muscle cell function if the original stimulus results in
smooth muscle cell dysfunction itself.
As the liver is the main site of XOR production and activity, our next goal was to
assess the impact of nitrite supplementation on the oxidative environment of the liver. We
used an in vivo immune-spin trapping method for indirectly assessing oxidant levels by
detecting free radicals resulting from the reaction of oxidants with biomolecules to form
stable, immunologically detectable nitrone-biomolecular adducts. We found that DMPO101

labeled adducts were significantly elevated in the liver of UCMS mice compared to
controls and that nitrite supplementation prevented this elevation. This decreased total
free radical production in the liver was further supported by the prevention of H 2O2
production (one of the typical by-products of XO) in the liver of chronically stressed mice
receiving nitrite supplementation. Concurrently, using western blotting technique, we
found that UCMS mice regardless of supplementation had increased XOR protein levels.
Taken together these data suggest that the mice undergoing chronic stress alongside
nitrite supplementation display altered product formation via XO that prevents the
induction of a pro-oxidative environment within the liver.
Liver XOR has been implicated in the facilitation of XO to the circulation resulting
in its distribution to alternative tissue sites (like the cerebrovasculature), resulting in
arterial dysfunction. Mice exposed to chronic stress did display an increase in plasma XO
activity, however, supplementation with nitrite prevented this increase in plasma activity.
Interestingly, others have noted that NO produced via XOR has the innate ability to limit
XOR activity, which may explain the lack of plasma XO activity in the nitrite supplemented
group that underwent chronic stress42,43. Given the proximity of the brain tissue with the
cerebrovasculature, we explored XOR protein and XO activity in brain homogenate. No
differences were noted in XOR protein or XO activity in the brain. However, H 2O2 was
significantly increased in the brain tissue of UCMS mice, and significantly reduced in the
UCMS+nitrite mice. Importantly, this persisted within the cerebrovasculature with UCMS
mice displaying a 2-fold higher production of H2O2 with supplementation with nitrite
preventing this increase. Taken together, these data suggest that nitrite supplementation
was sufficient at switching the by-products of XO away from H2O2 and O2●- in the liver,
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brain, and cerebral circulation, allowing for abundant NO production sufficient at
maintaining EDD of the MCA.
Our recent work has identified the potential clinical consequences of chronic stress
exposure on cognitive function, specifically working memory, with inhibition of XOR
preventing this decline in cognitive function6. Interestingly, nitrite supplementation did not
completely prevent this decline in the working memory of chronically stressed mice. In
human studies, the impact of nitrite supplementation on cognitive function has received
mixed results. In some studies, nitrite supplementation has a positive effect on cognitive
function44,45, however, in other studies, nitrite supplementation has no impact 46–48. It is
possible that these different results are either due to differences in the dose of nitrite
supplementation or the specific cognitive domain being assessed. However, it is possible
that this incomplete restoration of working memory with chronic stress and nitrite
supplementation is due to the innate ability of XO. Uric acid, O 2●-, as well as XO itself
have been identified as endogenous ligands for toll-like receptor 4 (TLR4)49–51.
Previously, we showed that inhibition of XO with febuxostat restored cognitive function 6.
Febuxostat completely inhibits XO activity, preventing the formation of uric acid and O 2●, therefore preventing the activation of TLR4 and driving an inflammatory response. Nitrite
supplementation, however, relies on XO activity to enzymatically convert nitrite to nitric
oxide; it is possible that the XO activity, as well as the uric acid production, are activating
TLR4, resulting in an inflammatory response that is having an impact on cognitive
function. In fact, lipopolysaccharide, a known antagonist of TLR4, has been shown to
have determinantal effects on cognitive function, with the inhibition of TLR4 preventing
cognitive decline by preventing a neuroinflammatory response52. Interestingly, those who
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have noted an improvement in cognitive function with nitrite supplementation also
reported a decline in inflammation44, therefore it may be possible that our dose of nitrite
was not sufficient as reducing inflammation or subsequent cognitive dysfunction.

Conclusions:
The present study exploited the chronic stress-induced upregulation of XO to
switch XO product formation from H2O2 and O2●- to NO. We show that supplementation
with sodium nitrite prevents the development of a pro-oxidative environment within the
liver, brain, and cerebrovasculature and therefore prevents the cerebrovascular
dysfunction associated with chronic stress. Sodium nitrite supplementation did not rescue
stress-induced deficits in working memory, possibly suggesting a role of inflammation in
chronic stress-induced cognitive decline.
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Figure Legends

Figure 1: Endothelium-dependent, and nitric oxide (NO)-dependent dilation. (A) Doseresponses to the endothelium-dependent dilator acetylcholine (ACh), and (B) MCA
maximal NO-dependent dilation = (Max DilationACh) – (Max DilationACh + L-NAME), in control,
and UCMS mice with or without chronic NO2- treatment. Panel A: *P<0.05 UCMS vs. all
other group's; Panel B, **p<0.01 UCMS; N = 15-20/group. Panel A, repeated measures
ANOVA (with tukey post-hoc test); panel B, one-way ANOVA with tukey post-hoc test.

Figure 2: Endothelial-independent dilator and constrictor response. (A) Dose-responses
of the MCA to the endothelial-independent dilator sodium nitroprusside (SNP), and (B)
the vasoconstrictor response to Phenylephrine (PE) in control, and UCMS mice with
(+NO2-) or without chronic NO2- treatment. *p<0.05 vs control; ^p<0.05 v control+NO2-;
+p<0.05 vs UCMS+ NO2-; mean±SD. n=17-20/group. Repeated measures ANOVA (with
tukey post-hoc test).

Figure 3: Maximal endothelial-dependent response and the role of oxidative stress.
Maximal dose-responses to the endothelial-dependent dilator acetylcholine (ACh), during
acute (30 min) incubation with a xanthine oxidase inhibitor Febuxostat. *p<0.05 vs no
incubation experiment within same group; mean±SD; n=15-21/group. Repeated
measures ANOVA (with tukey post-hoc test).
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Figure 4: Oxidative stress in the liver. (A) 5,5-Dimethyl-1-Pyrroline-N-Oxide (DMPO) was
used to detect free radical formation on biomolecules in the liver via western blotting; (B)
quantification of DMPO western blot. (C) Xanthine oxidase reductase (XOR)
concentration was assessed within the liver using western blotting techniques. (D)
representative XOR western blot image. (E) Liver XO activity measured with HPLC. (F)
Liver hydrogen peroxide production measured via CBA assay. *p<0.05; mean±SD. n=418/group. One-way ANOVA with tukey post-hoc test.

Figure 5: Plasma XO activit. Plasma XO activity was measured by HPLC * p<0.05
between groups; mean±SD. n=11-19/group. One-way ANOVA with tukey post-hoc test.

Figure 6: Oxidative stress in the brain. (A) 5,5-Dimethyl-1-Pyrroline-N-Oxide (DMPO)
was used to detect free radical formation on biomolecules in the brain via western blotting;
(B) quantification of DMPO western blot. (C) Xanthine oxidase reductase (XOR)
concentration was assessed within the brain using western blotting techniques. (D)
representative XOR western blot image. (E) Brain XO activity measured with HPLC.
mean±SD. n=4-11/group. One-way ANOVA with tukey post-hoc test

Figure 7: Oxidative stress within the brain and isolated brain microvessels. The CBA
assay was used to assess hydrogen peroxide production within (A) whole brain
homogenate and (B) isolated brain microvessels. ***p<0.001, ****p<0.0001 between
groups; mean±SD. n=7-12/group. One-way ANOVA with tukey post-hoc test.
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Figure 8: Locomotor and cognitive behavior with chronic stress. Open field test was used
to measure locomotor behavior with total horizontal movements via beam breaks (fine
and ambulatory combined) in the arena (A), and the number of vertical beam breaks
(rearing; B). Spontaneous alternation Y-maze test was used to measure locomotor
behavior (distance moved [C] and speed [D]) and working memory (E). * p<0.05 between
groups, mean±SD. n=10-18/group. One-way ANOVA with tukey post-hoc test.
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Table 1: Animal Characteristics
Control

Control+NO2-

UCMS

UCMS+NO2-

60%

55%

52.5%

51%

Body Mass (g)

27.1±4

27.9±3.4

25.5±3.3^

26±3.4

Mean Blood Pressure, mmHg

119±7.7

115±8.9

124±9.8

120±6.9

17.85 ± 11.07

15.82 ± 5.51

14.29 ± 7.49

32.24 ± 17.83+

112.3±78.9

118±37.2

230.4±132*^

133±59.4

0.7±1.2

1.3±1.3

6.1±1.4*^

6.2±1.4*^

8.5±7

12.5±10

19.5±17*

17.3±16*

43.7±19

36.7±19

24.7±15*^

24.4±15*^

Male (%)

Plasma Nitrate/nitrite
(n=7-8/group)
Corticosterone, (ng/ml)
Coat scores, AU
Sucrose splash test
Latency
# of licks

Mean±SD; *p<0.05 vs. Control, ^p<0.05 vs. Con+ NO2-, +p<0.05 vs. UCMS

n= 31-40/group except corticosterone and blood pressure n=10-12/group

Table 2. Active and passive middle cerebral artery responses

Control

Control+ NO2-

UCMS

UCMS+ NO2-

Active OD (µm)

94±17

97±10

98±16

83±10

Myogenic Tone (%)

34±8

35±8

28±12

32±11

ID (µm)

94±10

90±9

90±12

91±13

OD (µm)

122±13

119±9

118±13

117±14

WT (µm)

14±3

15±3

14±3

13±2

0.3±0.07

0.3±0.08

0.3±0.09

0.3±0.06

Passive

WLR

Pressure=60mmHg; Mean±SD, n=9-18/group.

OD= Outer Diameter
ID= Inner Diameter
WT= Wall Thickness
WLR= Wall to Lumen Ratio
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Abstract
Background: The aim of this study was to assess the role of Toll-like receptor 4 (TLR4)
in chronic stress-induced cerebrovascular dysfunction. We hypothesize that TLR4
knockout mice undergoing chronic stress will not have the typical cerebrovascular
dysfunction associated with chronic stress.
Methods and Results: 18-week-old male/female C57BL/10ScNJ (TLR4-/-) and
C57BL/6J (TLR4+/+) mice underwent 8 weeks of control conditions or unpredictable
chronic mild stress (UCMS). Excised middle cerebral arteries (MCA) were mounted in a
pressurize myobath and exposed to increasing concentrations of acetylcholine (ACh).
Nitrite supplementation prevented the UCMS-induced impaired ACh response in the
MCA. We examined xanthine oxidoreductase (XOR) protein abundance and hydrogen
peroxide production in the liver and brain. TLR4-/- mice exposed to chronic stress had
normal cerebrovascular function as a result of normal nitric oxide-dependent dilation and
displayed no pro-oxidative environment.
Conclusion: These data suggest that TLR4 plays a role in driving oxidative stress
(generates via xanthine oxidase) responsible for the cerebrovascular dysfunction
associated with chronic stress.
Key Words: UCMS, Middle Cerebral Artery, Xanthine Oixdase, Oxidative stress, Toll-like
Receptor 4
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Introduction
Chronic stress, defined as a state of threatened homeostasis aimed at allowing for
adaptation, has been identified as a leading cause of disease burden with 75% of people
reporting experiencing physiological stress that impaired either their mental or physical
health1. In fact, chronic stress has been identified as a powerful risk factor for the
development of various cerebrovascular diseases, such as stroke and dementia 2,3, which
are the leading cause of long-term disability and the second leading cause of death
worldwide4.
Our past work has shown that chronic stress induces cerebrovascular dysfunction
and xanthine oxidase (XO) is the primary force behind this dysfunction, as inhibiting this
pathway prevents the cerebrovascular dysfunction from forming 5. XO is a variant of the
xanthine oxidoreductase enzyme, most active under hypoxic or pro-inflammatory
conditions, and is responsible for converting xanthine to uric acid while producing
hydrogen peroxide (H2O2) and superoxide anions (O2●−)6. While the liver is the main
source of xanthine oxidoreductase, it is also the main source of circulating xanthine
oxidoreductase; when xanthine dehydrogenase is released from hepatocytes, it is
promptly converted into XO by plasma proteases and subsequently binds with high affinity
to the endothelial glycosaminoglycans (GAGs)7–9.
Recent work has identified an interaction between XO and toll-like receptor 4
(TLR4) on the surface of neutrophils10. TLR4 belongs to a family of pattern recognition
receptors located on microglia, neurons, and endothelial cells. Aside from recognizing
exogenous molecules, it also functions in the recognition of endogenous molecules (such
as XO) released from injured tissues and necrotic cells10–13 and results in the induction of
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an inflammatory response, a key component of the chronic stress response 14–17.
Importantly, this induction of a pro-inflammatory environment further drives XO activity18,
creating a viscous cycle resulting in an overall oxidative environment, responsible for
inducing cerebrovascular dysfunction.
The present study was designed to examine the role of TLR4 in chronic stressinduced cerebrovascular dysfunction. We hypothesized that knocking out TLR4 will
prevent the further activation of XO, preventing an oxidative environment from developing
and protecting the cerebrovasculature from insult.

Methods
Animals and group allocation: Male and female C57BL/10ScNJ (TLR4-/-) and
C57BL/6J (TLR4+/+) mice (Jackson Laboratory) arrived at the West Virginia University
Health Sciences Center (WVUHSC) animal facility at 7-8 weeks of age. After 1 week of
acclimation to the local environment, mice were randomly assigned to a specific protocol
group for the subsequent 8 weeks including 1) control (non-UCMS), 2) UCMS, 3) TLR4/- control, and 4) TLR4-/- UCMS. All animals were fed standard chow and tap water ad
libitum for all experiments. Protocols received prior approval from the WVUHSC Animal
Care and Use Committee.

Chronic Stress Intervention: As previously performed5, we used the Unpredictable
Chronic Mild Stress (UCMS) model to induce chronic stress in our mice. The UCMS
model is considered to be the most appropriate rodent model to elicit a chronic stress
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phenotype, based on its ability to reproduce anxiety-like behaviors as well as its ability to
lead to the development of symptoms related to the clinical consequences of chronic
stress such as anhedonia, learned helplessness, and memory impairment 19–22.
All mice were singly housed. In UCMS groups, mice were exposed to the following mild
environmental stressors in randomly chosen sequences for ~7 hours each day, 5
days/week, over the course of 8 weeks:
1. Damp bedding – 10 oz. of water was added to each standard cage
2. Bath – all bedding was removed and ~0.5 inches of water was added to empty
cage. Water temperature was room temperature, ~24°C
3. Cage Tilt - cage was tilted to 45 degrees without bedding
4. Social stress – each mouse was switched into a cage of a neighboring mouse
5. No bedding – all bedding was removed from the cage
6. Alteration of light/dark cycles –turning lights off/on in random increments for a
scheduled period.

Stress markers: At the time of death, plasma was collected, and using a commercially
available corticosterone ELISA kit (Arbor Assay, Item #K014), corticosterone levels were
examined in triplicate according to the manufacturer's instructions. During the duration of
the 8-week protocol, the rodent’s coats were evaluated. Each week the mice were
inspected for grooming habits23 and the total cumulative coat score was computed by
giving an individual score of 0 (clean) or 1 (dirty) to eight different body parts (i.e. head,
neck, back, forelimbs, stomach, hindlimbs, tail, genitals). Following the 8-week protocol,
sucrose splash testing was performed to assess grooming behavior. The sucrose splash
test consisted of spraying a 10% sucrose solution on the dorsal coat of a mouse in an
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empty cage; latency to begin grooming as well as frequency were recorded for a total of
5 minutes24.

Vascular reactivity/mechanics: Mice were euthanized and the brain was carefully
removed from the skull and placed in a cold physiological salt solution (PSS; 4ºC). Both
middle cerebral arteries (MCA) were dissected from their origin at the Circle of Willis and
placed into an isolated microvessel chamber (living systems) filled with PSS. Each MCA
was subsequently doubly cannulated within a heated chamber (37°C) that allowed the
lumen and exterior of the vessel to be perfused and superfused, respectively, with PSS
from separate reservoirs. The PSS was equilibrated with a 21% O 2, 5% CO2, and 74%
N2 gas mixture and had the following composition (mM): 119 NaCl, 4.7 KCl, 1.17 MgSO4,
1.6 CaCl2, 1.18 NaH2PO4, 24 NaHCO3, 0.026 EDTA, and 5.5 glucose. Any side branches
were ligated. MCA diameter was measured using television microscopy and an on-screen
video micrometer.

Measurements of Vascular Reactivity in Isolated MCA: Following cannulation, MCAs
were extended to their in-situ length and were equilibrated at 70 mmHg mean arterial
pressure. Active tone at the equilibration pressure was calculated as (ΔD/Dmax) × 100,
where ΔD is the diameter increase from rest in response to Ca2+-free PSS, and Dmax is
the maximum diameter measured at the equilibration pressure in Ca 2+-free PSS.
Following equilibration, the MCA dilator reactivity was assessed in response to increasing
concentrations of an endothelial-dependent dilator (EDD, acetylcholine; ACh, 10−9M –
10−4M), endothelial-independent dilator (EID, sodium nitroprusside; SNP 10−9M – 10−4M),
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and a potent vasoconstrictor (phenylephrine, PE 10 −9M – 10−4M). To assess the effects
of NO on EDD, the MCA was acutely incubated (30 minutes) with L-NAME (10−4 M) and
the MCA EDD response to ACh was repeated. To assess the acute effects of oxidative
stress on modulating EDD, we acutely (30 minutes) incubate the MCA with 1) TEMPOL
(10−4M, Sigma Aldrich, cat# 176141); and 2) febuxostat (10mM; Axon Medchem BV,
Netherlands). Following completion of all procedures, the perfusate and superfusate were
replaced with Ca2+-free PSS and the passive diameter of the fully relaxed MCA was
determined over an intralumenal pressure range of 5–140 mmHg at 20-mmHg pressure
increments. After 7 min at each intraluminal pressure, the inner and outer diameters of
the passive MCA were determined. Media thickness, lumen and outer diameters, and
vessel cross-sectional areas (used as indicators of structural alterations to the individual
microvessel) were determined as follows: Media thickness (WT, μm) = Outer diameter –
lumen diameter (i.e., OD – LD); media-to-lumen (M:L) ratio = MT/LD; Cross-sectional
area (μm2) = Outer vessel area – lumen area. Myogenic tone was assessed using the
following formula: 1-(active diameter/passive diameter)*100 (Rigsby, 2007). NOdependent dilation was determined from the maximal EDD in the absence or presence of
L-NAME according to the following formula: NO-dependent dilation (µm) = Maximum
dilationACh - Maximum dilationACh+L-NAME.

Tissue Oxidants: As briefly described below, the brain and liver were explored for
oxidative products.
Xanthine Oxidase-HPLC: XO activity was measured in the plasma, liver, and brain tissue
as previously described using high-performance liquid chromatography (HPLC)7,25.
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Samples were homogenized in ice-cold RIPA containing a protease inhibitor cocktail
(Sigma) and spun down. Tissue samples were processed as described below with a
sample volume of 10µL. Uricase was inhibited by oxonic acid (100 µM) to avoid an
underestimation of enzyme activity. Total XOR activity was determined on the basis of
the rate of uric acid production in the presence of xanthine (75 µM) and nicotinamide
adenine dinucleotide (NAD+, 0.5 mM). Allopurinol (100 µM), an inhibitor of XOR, was
used in parallel samples to confirm that urate formation was specific. After 60 min of
incubation at 37°C, the reaction was terminated by protein precipitation with cold
acetonitrile. The samples were then centrifuged for 12 min at 13,200 x g, at 4°C. Following
centrifugation, the supernatant was removed and placed in borosilicate glass tubes. After
a 60-minute dry-down process, the samples were resuspended in isocratic mobile phase
(300 µL) and filtered through a 0.20 µm nylon membrane filter unit into 11 mm plastic
snap-top auto-sampler vials. The uric acid content of protein-free samples was
determined by an HPLC-based electrochemical technique as described below. One unit
of activity (U) is defined as 1 µmole/min urate formed at 37°C and pH 7.4. Total protein
concentration was determined by the bicinchoninic acid method (BCA, Pierce).
Measurements were carried out blindly without knowledge by the operator of the animal
treatment groups. Uric acid was measured by electrochemical detection (Vanquish
UltiMate 3000 ECD-3000RS) coupled to reverse-phase HPLC using a Phenomenex
column (Luna 3µm C18(2) 100 A, 150x4.6 mm) and isocratic mobile phase (50 mM
sodium dihydrogen phosphate, 4 mM dodecyltrimethylammonium chloride, 2.5%
methanol, pH 7.0). Potentials for 3 channels were as follows: -100mV, 30mV, and 390mV.
Quantitation/integration was performed on the dominant peak. In the case of XO activity
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in plasma, 10-20 µL of plasma was used in lieu of tissue and processed with the same
protocol as above without gel filtration. XO activity in plasma utilized volume (U/mL) as a
denominator rather than protein.

Xanthine Oxidase-Western Blots: Liver and brain tissue were homogenized in 1x
PBS plus HALT inhibitor and then centrifuged at 3000 rpm at 4 °C for 20 min. An equal
amount of protein for each sample was loaded into a polyacrylamide gel. After the
completion of gel electrophoresis, the protein was transferred to nitrocellulose
membranes overnight. XO expression was assessed using a XO antibody (1:500; Santa
Cruz; cat # sc-398548) followed by a secondary antibody (1:10,000; Licor; cat # 92532201 and 925-68071). GAPDH (1:1000; Cell Signaling; cat #2118) was used as a
loading control. Blots were imaged using Licor Odyssey and band intensity was assessed
using ImageJ software.

Coumarin Boronic Acid (CBA) Assay: Hydrogen peroxide (H2O2) abundance was
measured in homogenate from the liver and brain using the CBA (Cayman #14051) assay
as previously described26. In brief, 10μg of lysates were loaded, in triplicate, into wells of
a 384-well black-sided clear bottom plate. Subsequently, assay buffer composed of HBSS
supplemented with 25 mM HEPES, 1% BSA, 10uM DTPA, 100uM l-NAME, 1 mM Taurine
was added and then CBA was added to each well at a final concentration of 0.5 mM. One
well from each biological sample received an additional 1 KU/ml bovine liver catalase to
act as a negative control. Upon addition of the CBA, plates were placed in a Biotek plate
reader preheated to 37°C and read kinetically at excitation 350 nm and emission 450 nm.
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The average rate of fluorescence was determined over the linear portion of the response
and then normalized by subtracting out the rate of fluorescence from the negative control.

Statistics: Data are presented as mean ± SD, unless otherwise stated. Normality was
evaluated by the Kolmogorov–Smirnov test, and outliers were identified using ROUT
analysis with a Q=1% and excluded from data presentation. As no statistical differences
were noted between male and female mice for all variables, male and female data were
combined for statistical approaches. The MCA maximal reactivity or the MCA remodeling
was analyzed by a multifactorial (experimental condition i.e., Control, UCMS, TLR4-/Con, and TLR4-/- UCMS) analysis of variance (ANOVA) with an interaction term, and a
Tukey post-hoc test was performed to determine differences between groups. The effects
of TEMPOL, Febuxostat, and L-NAME on the maximal dilation of the MCA were examined
with a repeated-measures ANOVA. Clinical characteristics between the animals were
compared with a One-Way ANOVA with Tukey post-hoc test, as appropriate. Data
analysis and graphing were conducted using GraphPad Prism version 9 software
(GraphPad Software, Inc.) and p ≤ 0.05 was set for statistical significance.

Results
Animal Characteristics and Stress Response: At the completion of the study, no
significant differences were noted in body mass between Con and UCMS, however,
TLR4-/- Con were significantly heavier than TLR4-/-UCMS groups (Table 1). Plasma
levels of corticosterone were significantly increased in the UCMS compared to Con or
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TLR4-/-Con (p<0.05). However, corticosterone levels were lower in the TLR4-/-UCMS
compared to UCMS mice (p<0.05), with no differences noted between TLR4-/-Con and
TLR4-/-UCMS mice (p>0.05). Behavioral assessments revealed poorer coat status of
mice undergoing UCMS as well as an increased latency to lick and a decreased number
of licks in the sucrose splash test compared to control mice (p<0.05). TLR4-/-UCMS mice
had a poorer coat score and slightly decreased number of licks in the sucrose splash test
(p=0.06) compared to controls.

MCA Function: The MCA’s endothelial-dependent dilator (EDD) responses in response
to increasing concentrations of ACh are summarized in Figure 1. Maximum EDD was
58% lower (p<0.001) in UCMS compared to control mice (Figure 1A). This impaired EDD
response was a result of a smaller ●NO dilator response as indicated by a smaller
reduction in EDD in the presence vs. absence of the ●NO inhibitor L-NAME (Figure 2B).
In contrast, MCA EDD in TLR4-/-UCMS was similar to Con and TLR4-/-Con mice (Figure
1) due to preservation of ●NO, that is ●NO dilator response was similar in Con, TLR4-/Con, and TLR4-/-UCMS mice (Figure 2B).
The endothelial-independent response of the MCA in response to increasing
concentrations of SNP was not affected by UCMS in either WT or TLR4 mice (Figure 3A).
However, both TLR4-/- groups had impaired MCA response to PE, a potent
vasoconstrictor, and UCMS did not alter this (Figure 2B).
To explore the role of oxidative stress on MCA function, we acutely incubated the
MCA with Tempol (a SOD mimic) or febuxostat (XO inhibitor) (Figure 4). In UCMS, both
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inhibitors of oxidative stress were equally as effective in restoring maximal EDD of the
MCA to Con levels. In the TLR4-/-UCMS mice, tempol and febuxostat incubation had no
additional benefit on the maximal MCA EDD.

MCA Wall Diameters and Stiffness: We next examined the extent to which UCMS affected
the structural phenotype of the MCA. MCA wall diameters, WT and wall to lumen ration
did not differ between groups, however TLR4-/- UCMS mice had higher myogenic
response compared to UCMS mice (Table 2).

XO and hydrogen peroxide: Liver XOR protein concentrations were increased with
chronic stress (p<0.05) compared to control mice (Figure 5A), however, in the TLR4-/UCMS mice, liver XOR protein concentrations were similar to Con, and TLR4-/-Con mice.
Next, we examined XOR protein concentrations in the brain and found no differences
between group's (Figure 5B). We then examined liver, brain and plasma XO activity. We
found no differences in liver XO activity between group's (Figure 6A). In contrast, XO
activity in the brain was significantly reduced in the TLR4-/-UCMS mice compared to all
other groups, with no differences brain XO activity between Con, UCMS, or TLR4-/-Con
mice (Figure 6B). Plasma XO activity was higher in UCMS mice vs. Con (p=0.07), and
significantly higher compared to TLR4-/-Con and TLR4-/-UCMS mice (Figure 6C), and no
differences were noted in plasma XO activity between Con, TLR4-/-Con and TLR4-/UCMS mice.
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As H2O2 is one of the main end products of the XO pathway, we used the CBA
assay to measure liver and brain H2O2 production. Liver H2O2 levels were higher in the
UCMS vs. Con, whereas liver H2O2 levels were similar between Con, TLR4-/-Con and
TLR4-/-UCMS mice (Figure 7A). Further, brain H2O2 levels were higher in the UCMS vs.
Cons, and although brain H2O2 levels were higher in the TLR4-/-UCMS vs. TLR4-/-Con
and Con, brain H2O2 levels were substantially lower in the TLR4-/-UCMS vs UCMS mice
(Figure 7B).

Discussion

In the present studies, we aimed to identify the role of TLR4 in chronic stressinduced cerebrovascular dysfunction. To do this, we exposed global TLR4 knockout
(TLR4-/-) mice to a chronic stress paradigm and assessed cerebrovascular function along
with the oxidative load. Major findings include: (1) TLR4-/- restores EDD in the MCA
primarily by maintaining NO signaling; (2) TLR4-/- prevents the oxidative environment
from developing in the liver and brain.

In previous experiments, incubating the MCA collected from mice exposed to
chronic stress with febuxostat, a XO inhibitor prevented EDD dysfunction 5. Furthering this
avenue of research, chronic supplementation with febuxostat not only prevented MCA
EDD from developing, but also prevented the oxidative environment from developing in
the liver, brain, and cerebral microvessels5. Taken together, these data emphasize the
importance of XO in driving the oxidative environment resulting in cerebrovascular
dysfunction with chronic stress. Interestingly, recent work has identified an interaction
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between XO and TLR4. Activation of TLR4 is an immune-sensitive mechanism triggered
by exogenous and endogenous molecules, including XO, resulting in the activation of an
inflammatory response, further driving XO activity, and contributing to the oxidative load 10.

Thus, to explore the interaction of TLR4 and XO, we exposed global TLR4-/male and female mice to 8 weeks of UCMS. TLR4-/- mice displayed a similar MCA
response to ACh as their genetic WT controls suggesting TLR4-/- in healthy mice does
not affect EDD. TLR4-/- mice exposed to UCMS had a normal MCA EDD response,
primarily driven by a normal NO dilation. This is consistent with work done by Nunes et
al, who showed that stimulation of the corpora cavernosa with angiotensin resulted in
decreased NO bioavailability, with simultaneous inhibition of TLR4 preventing this
decrease in NO bioavailability27. Further, TLR4 has been identified as a regulator of
Caveolin-1 (Cav-1) and Cav-1 is involved in eNOS translocation28–30. These data
suggest that chronic stress is upregulating TLR4 activity, which is leading to Cav-1
degradation and reduced eNOS activity. The normal EDD and NO dilation in TLR4-/UCMS mice support this hypothesis as inhibition of TLR4 prevents reduced NO
bioavailability, although future studies would have to assess the activity/expression of
Cav-1 as it relates to chronic stress. Additionally, the normal cerebrovascular function of
TLR4-/- UCMS mice is likely driven in part by the prevention of the formation of an
oxidative environment as incubation of these MCAs with tempol, a general superoxide
dismutase inhibitor, and febuxostat, a XO inhibitor, did not improve EDD any further.
Once again, this theory is consistent with work done by Nunes et al; in their study on
hypertension, inhibition of TLR4 prevented superoxide formation, suggesting that TLR4
plays an important role in driving the oxidative load27.
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We did identify a decrease in MCA constriction in both TLR4-/- groups, suggesting
TLR4 may be important in regulating smooth muscle tone and function. Others have
noted a decreased vascular sensitivity to noradrenalin (a vasoconstrictor) in mesenteric
vessels treated with an anti-TLR4 antibody31, confirming the idea that TLR4 may play a
role in regulating smooth muscle function. However, it is unclear how TLR4 may play a
role in regulating smooth muscle function as there is conflicting evidence in the field 32.

In order to understand the role of TLR4 on the development of an oxidative
environment with chronic stress, we first assessed the oxidative load within the liver as it
is the main source of XOR production7,8. As anticipated, the UCMS group had increased
XOR expression within the liver, while both TLR4-/- groups had a reduced XOR
expression, similar to control levels. These data was supported by the assessment of
H2O2 levels (the main by-product of XO) within the liver; mice exposed to chronic stress
had increased production of H2O2 while TLR4-/- UCMS had reduced H2O2 levels as
compared to the UCMS group. We hypothesized that knockout of TLR4 receptor would
prevent the continued development of an oxidative environment, however, it appears as
if knocking out TLR4 prevented the initial development of an oxidative environment within
the liver. This suggests that on top of XO activating TLR4, TLR4 or its downstream
products are activating XO. This is consistent with data showing incubation of cells with
LPS, a potent TLR4 activator, results in increased XO activity; interestingly incubating
these cells with LPS and febuxostat, a XO inhibitor, prevents this increase in XO activity 33.
This is one of the few pieces of evidence supporting the bidirectional relationship between
XO and TLR4.
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Within the brain, chronic stress had no impact on XO expression or activity while
TLR4-/- UCMS mice had decreased XO activity. As others have noted low XOR
expression and activity within the brain, these data were not surprising 34. However, an
increase in H2O2 production was noted in the UCMS group while the TLR4-/- UCMS group
was significantly lower than the UCMS group but significantly higher than the control
groups. This was quite interesting as these data were suggesting that XO was activating
TLR4 and TLR4 was further activating XO. If this were the case, it would be anticipated
that TLR4-/- UCMS group would have reduced H2O2 production, as seen in the liver.
However, this decrease in H2O2 production in TLR4-/- UCMS mice compared to WT
UCMS mice and increased H2O2 production in TLR4-/- UCMS mice compared to WT
control mice may be driven by the cerebral circulation. When XDH is released from
hepatocytes, it is rapidly converted to XO by plasma proteases within the circulation and
subsequently binds with high affinity to the endothelial glycosaminoglycans (GAGs)9. The
interaction of XO and GAGs alters XO kinetic properties, shifting oxidant product away
from O2●− to H2O26. Therefore, the increased production of H2O2 seen in the TLR4-/UCMS group may be driven by XO-GAG interactions on the cerebral endothelium. Taken
together, these data suggest that chronic stress induces a bidirectional relationship
between XO and TLR4 that drives the development of an oxidative environment, leading
to cerebrovascular dysfunction.
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Conclusions

The present study demonstrates the role of TLR4 in chronic stress-induced
cerebrovascular dysfunction. We showed that globally knocking out TLR4 prevented
cerebrovascular dysfunction by inhibiting the bi-directional relationship between XO and
TLR4 and preventing the development of an oxidative environment within the liver and
brain that is typically associated with chronic stress.
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Figure Legends

Figure 1: Middle cerebral artery endothelial-dependent dilation. Dose-response to the
endothelial-dependent dilator (EDD) acetylcholine (ACh) in control and UCMS mice, and
global Toll-like receptor 4 knock-out (TLR4) control and UCMS mice. * p<0.05 vs Con;
^p<0.05 vs TLR4-/- Control; +p<0.05 vs TLR4-/- UCMS; mean±SD. n=15-18/group.

Figure 2: Middle cerebral artery endothelial nitric oxide-dependent dilation. (A) Maximal
response to the endothelial-dependent dilator acetylcholine (ACh) with and without the
nitric oxide (NO) inhibitor L-NG-Nitro arginine methyl ester (L-NAME). (B) MCA maximal
NO-dependent dilation = (Max DilationACh) - (Max DilationACh+L-NAME). Data reflect Con and
UCMS mice and global Toll-like receptor 4 knock-out (TLR4-/-) control and UCMS mice.
Panel B *p<0.05 between groups. Mean±SD. n=15-17/group.

Figure 3: Middle cerebral artery endothelial-independent dilator and constrictor
response. (A) Dose-responses of the MCA to the endothelial-independent dilator sodium
nitroprusside (SNP), and (B) the vasoconstrictor response to phenylephrine (PE) in Con,
and UCMS mice and global Toll-like receptor 4 knock-out (TLR4-/-) control and UCMS
mice. ^p<0.05 vs TLR4-UCMS; +p<0.05 vs TLR4-Con; mean±SD. n=15-17/group.

Figure 4: Maximal endothelial-dependent response and the role of oxidative stress.
Maximal dose-responses to the endothelial-dependent dilator acetylcholine (ACh), during
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acute (30 min) incubation with Tempol, or Febuxostat. *p<0.05 vs no incubation
experiment within the same group. Mean±SD; n=8-19/group.

Figure 5: Xanthine oxidase reductase (XOR) concentration was assessed within the liver
(A) and brain (C) using western blotting techniques. B and D are representative XOR
western blot images. *p<0.05 between groups; mean±SD. n=5-11/group. One-way
ANOVA with tukey post-hoc test

Figure 6: XO activity. Liver (A), brain (B), and plasma (C) XO activity was measured with
HPLC. *p<0.05 between groups. mean±SD. n=6-22/group. One-way ANOVA with tukey
post-hoc test

Figure 7: Hydrogen peroxide production. The CBA assay was used to assess hydrogen
peroxide production within the liver (A) and brain (B). * p<0.05 between group's.
mean±SD. n=7-13/group. One-way ANOVA with tukey post-hoc test.
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Table 1: Behavioral Characteristics
Control

TLR4-/- Control

UCMS

TLR4-/- UCMS

50

50

48

50

27.6±4.4

33.2±5.6

26.3±3

26.7±3.2^

95.96±53.6

61.2±45.5

227.3±132.6*^+

69.66±34.9

1±1.3

1.6±1.6

5.5±1.4*^

5±1.5*^

6.4±5.9

7.9±6

19.9±13*

21.3±29.2

43.2±20

36.4±20

25.9±16*

Male (%)
Body Mass (g)
Corticosterone, (ng/ml)
Coat scores, AU
Sucrose splash test
Latency
# of licks

24.7±19
(p=0.06 vs control)
Mean±SD; *p<0.05 vs. Control, ^p<0.05 vs. TLR4-/- Con, +p<0.05 vs. TLR4-/- UCMS

n= 10-25/group

Table 2. Active and passive middle cerebral artery responses

Control

TLR4-/- Control

UCMS

TLR4-/- UCMS

Active OD (µm)

91.8±15

90.2±11

94.7±14

96.1±16

Myogenic Response

20.8±10

26±7#

15.3±9

21.4±10

ID (µm)

92±9

100±9

88±10

95±13

OD (µm)

120±12

123±9

116±12

121±12

WT (µm)

13.6±3.3

12.1±2.1

13.8±3

12.8±2.7

WLR

0.29±0.07

0.25±0.05

0.31±0.08

0.28±0.08

Passive

Pressure=60mmHg; Mean±SD; *p<0.05 vs. Control, #p<0.05 vs. UCMS n= 9-18/group

OD= Outer Diameter
ID= Inner Diameter
WT= Wall Thickness
WLR= Wall to Lumen Ratio
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Figure 3
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Figure 4
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Figure 6
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Figure 7
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Abstract
Background: Cerebrovascular impairments are a key pathology associated with
Alzheimer’s disease (AD). Past work in our lab has shown that chronic stress induces
cerebrovascular dysfunction due to a pro-oxidative environment while epidemiological
studies suggest a link between chronic stress and dementia. With this in mind, we tested
the hypothesis that chronic stress accelerates the vascular pathology associated with AD
potentially via the xanthine oxidase pathway
Methods and Results: We utilized a triple transgenic mouse model of AD (3xTg-AD)
alongside our unpredictable chronic mild stress (UCMS) paradigm and the xanthine
oxidase inhibitor, febuxostat. Beginning at 4 months of age, mice were either assigned
UCMS or non-UCMS with or without febuxostat. A subset of mice was sacked
immediately following UCMS at 6 months of age, while another subset was aged out to 9
months of age to assess the impact of chronic stress on accelerating AD pathology.
Excised middle cerebral arteries (MCA) were mounted in a pressurize myobath and
exposed to increasing concentrations of acetylcholine (ACh). At 6 months of age 3xTgAD mice and 3xTg-AD UCMS mice had impaired MCA response to ACh with febuxostat
preventing this impairment. At 9 months of age, 3xTg-AD UCMS mice had compounded
MCA impairment to ACh compared to 3xTg-AD controls and febuxostat prevented this
impairment.
Conclusion: These data suggest that chronic stress does accelerate the cerebrovascular
pathology associated with AD, potentially via activation of the XO.
Key Words: UCMS, 3xTg-AD mice, Middle Cerebral Artery, Xanthine Oxidase
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Introduction
Dementia, a major neurocognitive disorder characterized by a progressive decline
in cognitive function, currently affects more than 55 million people worldwide, and this
number of projected to rise to 139 million by 20501,2. Alzheimer’s disease (AD) is the most
common form of dementia, with it contributing to more than 60% of dementia cases2. AD
is typically characterized by amyloid plaques and neurofibrillary tangles; however, these
neuropathological changes occur in individuals with other forms of dementia as well as
cognitively healthy individuals3, suggesting new avenues of research into AD progression
are needed.
Comorbidities of the cerebrovasculature are frequently reported in patients with
AD. Epidemiological studies, such as the Rotterdam Study and the Honolulu-Asia Aging
Study, suggest arterial alterations are early events in cognitive deficits and one of the
strongest brain pathologies associated with AD4,5. Similarly, work in the APP/PS1
transgenic mouse model of AD showed alterations in brain microvasculature prior to the
onset of cognitive changes, suggesting vascular alterations were developing before the
typical dementia pathology6. Taken together, these data revealed a new avenue of
research into dementia and AD coined “vascular contributions to cognitive impairment
and dementia” (VCID)7–9. Within this concept of VCID, it is thought that typical dementia
pathology results from alterations within the cerebral circulation that result in glial and
neuronal changes, eventually resulting in neurodegeneration, cognitive decline, and
dementia10. Taken together, these data implicate cerebral alterations as a possible
biomarker of AD severity and progression, especially in the asymptomatic phase of the
disease.
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Our past work has shown that chronic stress induces cerebrovascular dysfunction,
and that xanthine oxidase (XO) may be a driving force behind this dysfunction 11,12. XO is
a variant of xanthine oxidoreductase (XOR) and is responsible for oxidizing hypoxanthine
to xanthine and xanthine to uric acid while producing hydrogen peroxide (H 2O2) and
superoxide anions (O2●−)13,14. The liver is the main source of XOR however following
hepatic stressors (i.e., inflammation, hypoxia), xanthine dehydrogenase can be released
from hepatocytes into the circulation, where it is rapidly converted to XO by plasma
proteases15,16.

XO

subsequently

binds

with

high

affinity

on

endothelial

glycosaminoglycans (GAGs), leaving it in a prime position to induce endothelial
dysfunction via oxidant production17. Interestingly, a twelve-year study showed a strong
association between vascular dementia and high serum uric acid 18, the product of XO
activity, suggesting that XO may play a role in the risk of dementia as well.
As chronic stress and AD share similar cerebrovascular pathology, the goal of this
study is to test the hypothesis that chronic stress accelerates the cerebrovascular
pathology associated with AD and to understand the role of XO in this pathology. It was
hypothesized that our AD mouse model would display cerebrovascular dysfunction
independently of stress and addition of chronic stress in this AD model would compound
the cerebrovascular dysfunction with inhibition of XO preventing this cerebrovascular
dysfunction across all groups.
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Methods
Animals and group allocation: Homozygous 3xTg-AD (3xTg-AD) and nonTg controls
(WT) (C57BL6/129S) were obtained from The Jackson Laboratory, and colonies were
bred and maintained at West Virginia University. This 3xTg-AD mouse model
progressively develops Aβ deposits and neurofibrillary tangles, the two main hallmarks of
AD, beginning around 6 months of age19–21. Starting at 4 months of age, male and female
3xTg-AD and WT mice were randomly assigned to a specific protocol group for the
subsequent 8 weeks including 1) WT control, 2) WT UCMS, 3) WT control+feb, 4) WT
UCMS+feb, 5) 3xTg control, 6) 3xTg UCMS, 7) 3xTg control+feb, and 8) 3xTg UCMS+feb.
A subset of mice was euthanized immediately following exposure to 8 weeks of chronic
stress at 6 months of age and another subset of mice was aged out until 9 months of age;
these timepoints were chosen as they allowed us to assess the impact of chronic stress
on the progression of AD cerebrovasculature pathology. All animals were fed standard
chow and water ad libitum for all experiments. Protocols received prior approval from the
WVUHSC Animal Care and Use Committee.
Febuxostat Treatment: Vehicle (standard drinking water) or febuxostat (Axon Medchem
BV, Netherlands) was delivered daily in the drinking water at a concentration of 50mg/L.
The water was measured frequently to calculate the concentration of drug consumed daily
(∼5–6 mg/kg per day) which was shown to effectively inhibit XO 22. Mice received
febuxostat supplemented water beginning at 4 months of age (beginning of chronic stress
paradigm) lasting until their euthanasia date (either 6 or 9 months of age). This allowed
us to assess the role of XO in the progression of AD cerebrovascular pathology with and
without chronic stress.
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Chronic Stress Intervention: As previously performed12, we used the Unpredictable
Chronic Mild Stress (UCMS) model to induce chronic stress in our mice. Every single
stressor (damp bed, cage tilt, cage reversal, etc) is of minor concern similar to humans
with one bad day among many average days. But with multiple stressors over 8 weeks
rodents cannot adapt, resulting in an increase in stress hormones and limited grooming.
All mice were singly housed. In UCMS groups, mice were exposed to the following mild
environmental stressors in randomly chosen sequences for ~7 hours each day, 5
days/week, over the course of 8 weeks:
1. Damp bedding – 10 oz. of water was added to each standard cage
2. Bath – all bedding was removed and ~0.5 inches of water was added to empty
cage. Water temperature was room temperature, ~24°C
3. Cage Tilt - cage was tilted to 45 degrees without bedding
4. Social stress – each mouse was switched into a cage of a neighboring mouse
5. No bedding – all bedding was removed from the cage
6. Alteration of light/dark cycles –turning lights off/on in random increments for a
scheduled period.
Stress markers: During the duration of the 8-week protocol, the rodent’s coats were
evaluated. Each week the mice were inspected for grooming habits 23 and the total
cumulative coat score was computed by giving an individual score of 0 (clean) or 1 (dirty)
to eight different body parts (i.e. head, neck, back, forelimbs, stomach, hindlimbs, tail,
genitals).
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Vascular reactivity/mechanics: Mice were euthanized and the brain was carefully
removed from the skull and placed in a cold physiological salt solution (PSS; 4ºC). Both
middle cerebral arteries (MCA) were dissected from their origin at the Circle of Willis and
placed into an isolated microvessel chamber (living systems) filled with PSS. Each MCA
was subsequently doubly cannulated within a heated chamber (37°C) that allowed the
lumen and exterior of the vessel to be perfused and superfused, respectively, with PSS
from separate reservoirs. The PSS was equilibrated with a 21% O 2, 5% CO2, and 74%
N2 gas mixture and had the following composition (mM): 119 NaCl, 4.7 KCl, 1.17 MgSO4,
1.6 CaCl2, 1.18 NaH2PO4, 24 NaHCO3, 0.026 EDTA, and 5.5 glucose. Any side branches
were ligated. MCA diameter was measured using television microscopy and an on-screen
video micrometer.
Measurements of Vascular Reactivity in Isolated MCA: Following cannulation, MCAs
were extended to their in-situ length and were equilibrated at 70 mmHg mean arterial
pressure. Active tone at the equilibration pressure was calculated as (ΔD/Dmax) × 100,
where ΔD is the diameter increase from rest in response to Ca 2+-free PSS, and Dmax is
the maximum diameter measured at the equilibration pressure in Ca 2+-free PSS.
Following equilibration, the MCA dilator reactivity was assessed in response to increasing
concentrations of an endothelial-dependent dilator (EDD, acetylcholine; ACh, 10−9M –
10−4M), endothelial-independent dilator (EID, sodium nitroprusside; SNP 10−9M – 10−4M),
and a potent vasoconstrictor (phenylephrine, PE 10 −9M – 10−4M). To assess the effects
of NO on EDD, the MCA was acutely incubated (30 minutes) with L-NAME (10−4 M) and
the MCA EDD response to ACh was repeated.
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Statistics: Data are presented as mean ± SD, unless otherwise stated. Normality was
evaluated by the Kolmogorov–Smirnov test, and outliers were identified using ROUT
analysis with a Q=1% and excluded from data presentation. As no statistical differences
were noted between male and female mice for all variables, male and female data were
combined for statistical approaches. The MCA maximal reactivity or the MCA remodeling
was analyzed by a multifactorial (experimental condition i.e., Control, UCMS, Con+feb,
and UCMS+feb) analysis of variance (ANOVA) with an interaction term, and a Tukey posthoc test was performed to determine differences between groups. The effects of L-NAME
on the maximal dilation of the MCA were examined with a repeated-measures ANOVA.
Clinical characteristics between the animals were compared with a One-Way ANOVA
with Tukey post-hoc test, as appropriate. Data analysis and graphing were conducted
using GraphPad Prism version 9 software (GraphPad Software, Inc.) and p ≤ 0.05 was
set for statistical significance.

Results
Animal Characteristics and Stress Response:
At the completion of the study, no significant differences were noted in body mass
between groups at either 6 or 9 months of age. Behavioral assessment revealed poorer
coat status of mice undergoing UCMS regardless of treatment in both the WT and 3xTgAD groups at 6 months. At 9 months mice undergoing WT UCMS and 3xTg-AD UCMS
had slightly poorer coat scores than their respective controls (p=0.06 and p=0.08,
respectively) (Table 1).
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MCA Function:
The endothelial-dependent dilator (EDD), endothelial-independent dilator (EID),
and constrictor responses of the WT MCA in response are summarized in Fig 1. WT mice
exposed to UCMS displayed an impaired EDD response to ACh compared to control mice
at both 6 and 9 months (Fig 1A and 1B, respectively). At both time points chronic
febuxostat treatment prevented this EDD impairment in WT mice exposed to chronic
stress (Fig 1A and 1B). There were no differences noted in MCA EID response to SNP
or MCA constrictor response to PE at either 6 or 9 months of age (Figure 2C-F).
The EDD, EID, and constrictor responses of the 3xTg MCA response are
summarized in Fig 2. For simplicity’s sake, maximal EDD, EID, and constriction response
will be discussed in Fig 3 and 4. The EDD response of the MCA in response to the max
concentration of ACh is summarized in Fig 3A. At 6 months of age an impaired EDD was
seen in 3xTg mice to WT controls (p<0.05) and similar to WT UCMS mice; 3xTg UCMS
did not display compounded impairment compared to 3xTg mice (Fig 3A). This impaired
EDD response was a result of a smaller NO dilatory influence, as indicated by a smaller
reduction in EDD in the presence vs. absence of the NO inhibitor L-NAME (p<0.05; Fig
3C). Chronic febuxostat treatment prevented this impaired EDD in 3xTg and 3xTg UCMS
mice by rescuing NO mediated dilation (p<0.05; Fig 3A and C). At 9 months of age, the
impaired EDD persisted in 3xTg mice as compared to control and 3xTg UCMS mice
displayed a compounded EDD impairment compared to 3xTg mice; both EDD
impairments were driven by smaller NO dilatory influence (p<0.05; Fig 3B and D). Chronic
febuxostat treatment prevented this impaired EDD in 3xTg and 3xTg UCMS mice by
rescuing NO mediated dilation (p<0.05; Fig 3B and D). MCA EID in 3xTg mice was
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impaired compared to WT controls at 6 months of age (p<0.05) but this impairment did
not persist at 9 months of age (Fig 4A and B). Comparatively, no MCA constriction
impairment was noted at 6 months of age, however, at 9 months of age, 3xTg UCMS
mice had an impaired constrictor response compared to WT controls (P<0.05; Fig 4C and
D). Chronic febuxostat treatment did not alter MCA EID or constrictor responses.

Discussion
The current pilot study was undertaken to understand the relationship between
chronic stress and AD as it relates to cerebrovascular pathology and the role of XO in this
pathology. To accomplish our goal, 3xTg-AD mice and genetic controls were exposed to
a well-documented chronic stress paradigm while a subset of these mice received
febuxostat supplemented water to assess the role of XO. At 6 months of age, immediately
following exposure to chronic stress and treatment, the cerebrovascular function was
assessed in one subset of mice while another subset of mice was aged out to 9 months
to assess the progression of AD pathology. A number of novel observations were made
in this current study: 1) 3xTg mice display impaired EDD function compared to WT control
mice, similar to WT UCMS mice at 6 and 9 months of age; 2) at 6 months of age 3xTg
mice and 3xTg UCMS mice have similar MCA EDD responses; 3) at 9 months of age
3xTg UCMS mice have impaired MCA EDD responses compared to 3xTg mice; 4) chronic
febuxostat treatment prevents this MCA EDD dysfunction in both 3xTg mice and 3xTg
UCMS mice.
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Past work in our lab has used the UCMS paradigm as a model for chronic
stress11,12. Here, using a different mouse strain, we confirmed the efficiency of the UCMS
paradigm at elucidating a chronic stress phenotype as mice exposed to UCMS,
regardless of genotype or treatment, had poorer coat scores than their control
counterparts at both time points. In this current study, we also confirmed that these
genetic WT mice have similar MCA responses to both chronic stress and febuxostat
treatment as our previous strain of mice.
Preclinical

and

epidemiological

studies

show

comorbidities

of

the

cerebrovasculature are frequently associated with AD4–6. Here, we show that at 6 months
of age, an age at which this strain of mice doesn’t have typical AD pathology, 3xTg-AD
mice have an impaired EDD MCA response compared to their WT control. This is
consistent with the knowledge that cerebrovascular alterations may be a preclinical
marker for the development of AD24,25. Importantly, at 9 months of age, an age at which
this strain

of

mice is typically developing

AD pathology19,

non-progressive

cerebrovascular impairment was seen, suggesting cerebrovascular dysfunction does
occur prior to typical AD pathology. We further noted that at both 6 and 9 months of age,
this MCA impairment in 3xTg-AD mice was driven by impaired NO dilatory response. This
is consistent with work done by Venturelli, et.al, who showed that dementia severity was
negatively correlated with NO bioavailability26. Further, chronic inhibition of NO production
in a mouse model of AD has been seen to exacerbate AD pathology, driving the
importance of nitric oxide in the development of AD pathology27.
There is growing evidence that chronic stress can accelerate AD pathology28–30. In
fact, in our previous study, we saw that chronic stress can induce cognitive impairment12.
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As both AD and chronic stress induce cerebrovascular dysfunction, our next goal was to
understand the interplay between chronic stress and AD cerebrovascular pathology. At 6
months of age, 3xTg-AD mice that underwent UCMS had similar MCA function as
compared to 3xTg-AD mice, however, at 9 months of age 3xTg-AD UCMS mice had a
significant impairment compared to 3xTg-AD mice. Others who have looked at the
interplay between chronic stress and cognitive function have noted that exposure to
chronic stress leads to worsened memory, exacerbated Aβ production, and increased tau
phosphorylation31,32. These accelerated AD pathologies were thought to be due to a
dysregulated stress response. Carroll et. al., showed in 8 month of PS19 mice (mice
harboring mutant human tau), that inhibition of corticotropin-releasing factor (CRF)
blocked tau pathology development, neurodegeneration, and learning impairments
associated with chronic stress while CRF overexpression mice showed enhanced
neurodegeneration and learning impairments at 10 months of age 31. Further,
Sotiropoulos, et. al., showed that administration of exogenous glucocorticoids in healthy
rats resulted in increased tau phosphorylation32. Taken together, these data suggest that
dysregulation of the stress response may be to blame for the compound effects of chronic
stress and AD on cerebrovascular function. Importantly, dysregulation of the stress
response has been linked to increased oxidative stress33–35 and we have shown that
oxidative stress, specifically driven by XO, is integral to chronic stress-induced
cerebrovascular dysfunction12.
Our past work shows that chronic stress increases activity within the XO pathway,
inducing an oxidative environment that drives cerebrovascular dysfunction; importantly
inhibiting xanthine oxidase not only prevented cerebrovascular dysfunction, but it also
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prevented the cognitive impairment seen in our chronically stressed mice12. With this in
mind, we wanted to assess the role of XO in cerebrovascular dysfunction with AD. To do
this, 3xTg-AD mice were given febuxostat supplemented water to inhibit XO. At 6 and 9
months of age, 3xTg-AD mice that received febuxostat had rescued MCA EDD compared
to 3xTg-AD mice. Further, at 6 and 9 months of age, 3xTg-AD mice that underwent
chronic stress and received febuxostat supplementation had rescued MCA EDD
compared to 3xTg-AD UCMS mice. These data suggest that XO plays a role in
pathological cerebrovascular dysfunction associated with AD, with and without chronic
stress. It is likely that inhibition of XO prevents the formation of an oxidative environment
and dysregulation of the stress response, preventing the cerebrovascular dysfunction
associated with both chronic stress and AD.

Limitations and future directions
As this was a pilot study that provided important and novel insights into the role of
chronic stress and XO on cerebrovascular pathology with AD, future studies will be
required to fully address this important topic. The study presented here utilized both male
and female mice and saw no sex differences, however, the number of mice per group
was relativity low which may not have allowed for enough power to see sex differences.
It is important that this study expand as several sex differences have been noted in the
3xTg-AD model ranging from amyloid-β burden to behavioral alterations36–39. Further, the
study presented here does not encompass behavioral alterations with AD or chronic
stress and it is important future studies include these as both AD and chronic stress have
unique effects on behavioral outcomes, especially memory. Finally, experiments
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assessing typical AD pathology (i.e., amyloid-β and tau phosphorylation) are needed to
fully understand the impact of chronic stress and AD on accelerating AD pathology as it
related to cerebrovascular function.

Conclusions
The present study was undertaken to understand the relationship between chronic
stress and AD as it relates to cerebrovascular pathology and the role of XO in this
pathology. We show that 3xTg-AD mice have cerebrovascular impairments compared to
WT control mice (independent of age) and 3xTg-AD mice exposed to chronic stress had
compounded cerebrovascular impairment at 9 months of age. Chronic febuxostat
prevented this cerebrovascular impairment in both 3xTg-AD and 3xTg-AD UCMS mice,
suggesting XO plays a role in both AD and chronic stress-induced cerebrovascular
dysfunction.
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Figure Legends
Figure 1: WT MCA response at 6 and 9 months of age. Endothelial-dependent dilation
at 6 months (A) and 9 months (B). Endothelial independent dilation at 6 months (C) and
9 months (D). Constrictor response at 6 months (E) and 9 months (F). * p<0.05 vs WT
Control; + p<0.05 vs WT control+Feb; ^ p<0.05 vs WT UCMS+Feb; mean±SD. n=59/group. Repeated measured ANOVA (with tukey post-hoc test).

Figure 2: 3xTg MCA response at 6 and 9 months of age. Endothelial-dependent dilation
at 6 months (A) and 9 months (B). Endothelial independent dilation at 6 months (C) and
9 months (D). Constrictor response at 6 months (E) and 9 months (F). * p<0.05 vs WT
Control; + p<0.05 vs 3xTg control+Feb; ^ p<0.05 vs 3xTg UCMS+Feb; #p<0.05 vs 3xTg.
mean±SD. n=5-9/group. Repeated measured ANOVA (with tukey post-hoc test).

Figure 3: 3xTg EDD MCA response at 6 and 9 months of age. Endothelial-dependent
dilation at 6 months (A) and 9 months (B). MCA maximal NO-dependent dilation = (Max
DilationACh) - (Max DilationACh+L-NAME), at 6 months (C) and 9 months (D). * p<0.05 vs
specified group; mean±SD. n=5-8/group. One way ANOVA (with tukey post-hoc test).

Figure 4: 3xTg MCA response at 6 and 9 months of age. Endothelial-indepdent dilation
at 6 months (A) and 9 months (B). MCA constriction at 6 months (C) and 9 months (D).
* p<0.05 vs specified group; mean±SD. n=5-9/group. One way ANOVA (with tukey posthoc test).
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Table 1: Behavioral Characteristics at 6 months of age

6 months of age
WT
Control

WT
UCMS

WT
Control
Feb

WT
UCMS
Feb

3xTg

3xTg
UCMS

3xTg Feb

3xTg
UCMS
Feb

Body Mass (g)

29±5

27±5

26±6

29±5

25±4

27±5

24±3

25±4

Coat scores, AU

0.6±1

5±1.3*^

1.2±1.6

4.8±1.7*^

0.4±0.5

5.2±1.6*^

0.7±0.9

4.9±1.6*^

Mean±SD; *p<0.05 vs. genetic control, ^p<0.05 vs. genetic control+feb

n= 8-18/group

Table 2: Behavioral Characteristics at 9 months of age
9 months of age
WT
Control

WT
UCMS

WT
Control
Feb

WT
UCMS
Feb

3xTg

3xTg
UCMS

3xTg Feb

3xTg
UCMS
Feb

Body Mass (g)

35±13

30±5

30±8

31±6

25±5

31±7

25±3

26±4

Coat scores,
AU

0.1±0.4

2.2±1.6

0.8±1

1.5±1.3

0.3±0.5

0.4±0.7

1.4±1.5

(p=0.06 vs
WTcontrol)

1.9±1.6
(p=0.08 vs
3xTg)

Mean±SD; *p<0.05 vs. genetic control, ^p<0.05 vs. genetic control+feb n= 4-10/group
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Figure 2
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Discussion
The purpose of this dissertation was to gain mechanistic insight into chronic stressinduced cerebrovascular dysfunction. It is well known that chronic stress, a precursor to
many diseases, leads to cerebrovascular dysfunction. Prior to these chapters, however,
little was known about the mechanisms behind chronic stress-induced cerebrovascular
dysfunction. The work detailed in this dissertation determines: (1) chronic stress induces
an oxidative environment in the liver, brain, and cerebral circulation, resulting in
cerebrovascular dysfunction; (2) this oxidative environment is driven by xanthine oxidase
(XO) as inhibition and manipulation of this pathway prevents the development of an
oxidative load and cerebrovascular dysfunction; (3) genetic knockouts of proposed
downstream targets of XO (i.e. TLR4) prevents the development of oxidative environment
and cerebrovascular dysfunction; (4) chronic stress-induced cognitive impairment is
driven by the XO pathway.
The second chapter of this dissertation focuses on the role of XO in the
development of an oxidative environment that drives cerebrovascular dysfunction with
chronic stress. Oxidative stress is a driving force behind arterial dysfunction and our past
work in a rat model has shown that oxidative stress plays an important role in MCA
dysfunction associated with chronic stress as:1) the oxidative load in the MCA of male
UCMS rats was 2-fold higher vs. controls1, and 2) acute inhibition of oxidative stress with
tempol rescued MCA function in male UCMS rats1. Previous work has shown that chronic
stress increases xanthine oxidoreductase (XOR) and XO activity leading to an
accumulation of oxidative stress within the visceral adipose tissue, liver, and intestines;
importantly inhibition of XO with febuxostat prevented this accumulation of oxidative
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stress2. The study presented in chapter 2 utilizes the UCMS paradigm alongside chronic
supplementation with febuxostat to understand the role of XO in chronic stress-induced
cerebrovascular dysfunction. We confirm, in a mouse model, that chronic stress-induced
endothelial-dependent dilation (EDD) dysfunction while producing an oxidative
environment within the liver and brain, specifically the cerebral circulation. Further,
chronic febuxostat supplementation prevented the MCA EDD dysfunction by maintaining
nitric oxide (NO) dependent dilation while preventing the development of an oxidative
environment within the liver, brain, and cerebrovasculature.
The findings of this chapter provide evidence that XO is driving the formation of an
oxidative environment that is eliciting cerebrovascular dysfunction and cognitive
impairment. Chronic supplementation with febuxostat rescues NO-mediated dilation
preventing MCA EDD suggesting XO either directly inhibits endothelial nitric oxide
synthase (eNOS)3 or leads to eNOS uncoupling and the production of peroxynitrite,
resulting in decreased NO bioavailability4,5. Further experiments would need to be
completed to confirm this exact mechanism of XO reducing NO bioavailability. The next
goal of this chapter was to understand the source of XO. The liver, one of the main
sources of XOR6,7, showed evidence of increased XO activity with chronic stress, and
febuxostat supplementation prevented this increase in XO activity. While also being one
of the main sources of XOR, the liver has also been implicated in the facilitation of XO to
the circulation resulting in distribution to alternative tissue sites8. UCMS did in fact
increase XO activity within the circulation and evidence of increased XO activity in the
brain and cerebrovasculature was noted; all of which was blunted with febuxostat
supplementation. These data suggest that chronic stress is facilitating the release of
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xanthine dehydrogenase (XDH) from the liver where it is converted to XO by plasma
proteases in the circulation8; as XO has a high affinity for glycosaminoglycans (GAGs) on
the endothelium8, XO is in a prime position to induce an oxidative environment with the
cerebrovasculature as well as the brain itself. However, XOR has also been noted in
endothelial cells by numerous studies9,10 suggesting chronic stress may be increasing XO
activity directly within endothelial cells themselves. Further experiments utilizing organspecific genetic XOR knockouts would be needed to confirm the particular source of XO
activity that is driving the oxidative environment responsible for cerebrovascular
dysfunction with chronic stress.
The third chapter of this dissertation aimed to manipulate the elevation of XO with
chronic stress to switch XO product formation from hydrogen peroxide (H 2O2) and
superoxide anions (O2●-) to NO by flooding the system with nitrite (NO2-). Previous
evidence shows that XO is the primary endogenous pathway responsible for catalyzing
the reduction of NO2- to NO, a potent vasodilator11. The study here utilizes our UCMS
paradigm alongside chronic sodium nitrite supplementation to assess the impact of nitrite
supplementation on the development of an oxidative environment and cerebrovascular
dysfunction typically associated with chronic stress. We found that chronic sodium nitrite
supplementation while undergoing UCMS prevented MCA EDD by rescuing NOdependent dilation. It was also noted that chronic nitrite supplementation prevented the
development of an oxidative environment in the liver, brain, and cerebral circulation.
The outcomes in this chapter show that exploiting the upregulation of XO with
chronic stress by flooding the system with NO2- improves cerebrovascular function by
diminishing the pro-oxidative environment and providing excess NO. Chronic
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supplementation with sodium nitrite during the duration of chronic stress rescued NOdependent dilation by preventing the development of MCA EDD. This rescued NOdependent dilation was likely two-fold: (1) by providing abundant NO bioavailability
through the enzymatic conversion of NO2- to NO and (2) by switching the by-products of
XO activity from H2O2 and O2●- to NO preventing the development of an oxidative
environment. In support of this, sodium nitrite supplementation prevented the
development of a pro-oxidative environment in the liver, brain, and cerebral circulation.
The fourth chapter of this dissertation was designed to examine the role of toll-like
receptor 4 (TLR4) in the development of an oxidative environment leading to
cerebrovascular dysfunction as a result of chronic stress. TLR4, an important pattern
recognition receptor within the immune system, has been shown to interact with XO 12,
resulting in the induction of an inflammatory response that further drives XO activity,
stimulating further production of an oxidative environment. The study here utilizes a global
TLR4 knockout mouse model (TLR4-/-) alongside our UCMS paradigm to explore the role
of TLR4 in the generation of an oxidative environment that drives cerebrovascular
dysfunction. We found TLR4-/- mice exposed to chronic stress did not display an oxidative
environment within the liver and brain and had normal cerebrovascular function due to
rescued NO-dependent dilation.
The findings of this chapter confirm the hypothesis that TLR4 plays a role in the
development of cerebrovascular dysfunction with chronic stress. TLR4-/- mice exposed
to UCMS had normal EDD due to rescued NO-dependent dilation. As neither acute
incubation of the MCA with tempol nor febuxostat improved EDD further, it is likely this
rescued NO-dependent dilation in TLR4-/- UCMS mice is due to the prevention of the
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development of an oxidative environment. As explained above, the prevention of this
oxidative environment will prevent the direct and indirect decrease in NO bioavailability,
allowing for normal MCA EDD function. Additionally, new research identified TLR4 as a
regulator of Caveolin-1 (Cav-1) which is involved in promoting eNOS activity13; future
studies would need to assess the impact of chronic stress on Cav-1 as well as the role of
XO and TLR4 in the predicted dysregulation. It was also noted that there was a general
decrease in oxidative stress within the liver and brain, with the slight increase in H2O2
being a result of the endothelial cell-GAG interaction which alters kinetic properties of XO
and shifts oxidant products toward H2O2. This lack of oxidative stress suggests that not
only does XO activate TLR4 but TLR4 and its downstream products drive XO activity,
generating a cyclic relationship that is responsible for driving the oxidative environment
and creating cerebrovascular dysfunction.
Chapters 2 and 3 also provide insight into the effect of chronic stress on cognitive
function as well as the role of XO in cognitive function. Chronic stress has been
consistently associated with poor cognitive function14–16, accelerated cognitive
decline17,18, and increased incidence of dementia17. In conjunction with this, recent work
has identified increased serum uric acid levels in patients diagnosed with vascular
dementia19,20. As a reminder, the study presented in chapter 2 utilized our UCMS
paradigm in combination with febuxostat, a XO inhibitor while the study presented in
chapter 3 utilized our UCMS paradigm in combination with sodium nitrite supplementation
(to exploit the XO pathway and improve NO bioavailability). Consistent with the literature,
the first key finding presented here was the reduction of cognitive function with chronic
stress. The second key finding was that supplementation with febuxostat while
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undergoing UCMS prevented these reductions in cognitive function. The third key finding
was the supplementation with sodium nitrite and manipulation of the XO pathway did not
prevent these reductions in cognitive function.
These findings presented in these two chapters provide insight into the potential
clinical consequences of chronic stress as it relates to cognitive function. Epidemiological
data21,22 and preclinical studies23,24 support the idea that arterial alterations are early
events in cognitive decline and that chronic stress can lead to cognitive decline25. The
relationship between chronic stress and cognitive decline is particularly important for the
health of older adults who are at greater risk for developing dementia. These data are
consistent with the two-hit vascular hypothesis of AD in which the compromised health of
the cerebrovasculature with chronic stress is an initial insult that is sufficient to initiate
neural injury and neurodegeneration, promoting the accumulation of amyloid β-peptide
and tau accumulation and phosphorylation. In fact, animal studies have shown a link
between stress and the neuropathology associated with dementia, demonstrating that
stress is associated with synapse loss26, increases in amyloid β-peptide27,28, and tau
accumulation and phosphorylation29. There is a known link between oxidative stress
leading to cerebrovascular dysfunction and cognitive decline 1,30. Here, we confirm this
link as chronic inhibition of XO alongside chronic stress prevents this decline in cognitive
function.
Interestingly, chronic sodium nitrite supplementation did not fully prevent the
cognitive

decline

associated

with

chronic

stress.

In

human

studies,

nitrite

supplementation has mixed results on cognitive function; in some studies, nitrite
supplementation has positive effects on cognition31,32 whereas in others nitrite
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supplementation has no impact on cognitive function 33–35. This incomplete restoration of
cognitive function with nitrite supplementation may be due to the innate ability of XO to
interact with TLR4, further driving oxidative stress and inflammation12,36,37. Sodium nitrite
supplementation relies on XO activity to enzymatically convert nitrite to NO; therefore, XO
may be having indirect effects that result in impaired cognitive function but not
cerebrovascular dysfunction. Interestingly, those who have noted an improvement in
cognitive function with nitrite supplementation also reported a decline in inflammation31,
suggesting that is it possible that our dose of nitrite was not sufficient at reducing
inflammation or subsequent cognitive dysfunction. Future studies would be needed to
assess cognitive function in TLR4 knockout models to confirm the role of TLR4 in the
incomplete restoration of cognitive function with sodium nitrite supplementation and
chronic stress.
Taken together these data provide insight into the potential mechanisms behind
chronic stress-induced cerebrovascular dysfunction and cognitive decline. We show here
that chronic stress is sufficient at inducing cognitive decline and cerebrovascular
dysfunction that is driven by oxidative stress generated by the XO pathway. Inhibition of
the XO pathway with febuxostat prevents not only cerebrovascular dysfunction with
chronic stress but also cognitive decline; these data suggest that oxidative stress and
cerebrovascular dysfunction play a role in cognitive function. However, nitrite
supplementation, while rescuing cerebrovascular function does not completely rescue
cognitive function. This data does not discredit the proposed theory as nitrite
supplementation is primarily aimed at rescuing vascular function by flooding the system
with NO and preventing oxidative stress, but it does not take into consideration the
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downstream targets of XO activity (i.e., TLR4 and inflammation) that may influence
cognitive function.
With our understanding of the impact of chronic stress on cerebrovascular function
and cognitive function, chapter 5 is a preliminary study that was undertaken to begin to
understand the relationship between chronic stress and AD as it relates to
cerebrovascular pathology and the role of XO in this pathology. Both AD and chronic
stress have been well characterized to elicit cerebrovascular dysfunction and data
presented in their dissertation as well as recent studies in humans identify XO as a
possible contributor to this cerebrovascular dysfunction. The study here utilizes a 3xTgAD mouse model in conjunction with our chronic stress paradigm and chronic febuxostat
supplementation to assess the interplay between chronic stress and AD as it relates to
the development of cerebrovascular function and understand the role of XO in this
function. We found that 3xTg-AD mice display impaired MCA EDD compared to WT
controls, similar to WT UCMS mice. At 6 months of age, 3xTg-AD mice and 3xTg-AD
UCMS mice had similar MCA EDD impairment but at 9 months of age 3xTg-AD UCMS,
mice showed compounded MCA EDD impairment compared to 3xTg-AD mice. Chronic
febuxostat supplementation prevented this MCA EDD impairment in all 3xTg-AD groups.
The outcomes in this chapter confirm that cerebrovascular alterations are a
preclinical marker for the development of AD, as 3xTg-AD mice show cerebrovascular
dysfunction at 6 months of age, prior to the onset of typical AD pathology in this particular
strain of mice. Further, we show that chronic stress compounds the MCA EDD impairment
in 3xTg-AD mice at 9 months of age compared to 3xTg-AD mice at 6 months of age. All
3xTg-AD groups supplemented with febuxostat had improved MCA EDD function as a
182

result of rescued NO-dependent dilation, suggesting that XO plays a role in the
cerebrovascular function of chronic stress, AD, and compounded impairment of chronic
stress and AD together. While these data introduce important evidence into the interplay
between chronic stress and AD as it relates to cerebrovascular function, future
experiments will be needed to understand the specific impact of chronic stress on general
AD pathology (i.e., amyloid β plaques and tau accumulation) as well as the role of XO in
the generation of these pathologies.
The work presented in this dissertation provides novel insight into the mechanisms
behind chronic stress-induced cerebrovascular dysfunction as well as introduces
potential clinical consequences of chronic stress-induced cerebrovascular dysfunction.
Taken together, these data implicate a cyclic relationship between XO and TLR4 that
drives the pro-oxidative environment responsible for generating cerebrovascular
dysfunction. Importantly, this work has long-term implications in the field of dementia
research as inhibition of XO prevents the cognitive impairment associated with chronic
stress. The potential clinical consequences of this research drove a preliminary study
showing the acceleration of AD cerebrovascular pathology with chronic stress and
identifying XO as the mechanism behind it. The continuation of this study could provide
valuable insight into the impact of chronic stress on preclinical characteristics of AD as
well as identify potential treatment avenues that may improve the quality and quantity of
life for many individuals suffering from dementia.
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Future Directions
The dissertation presented here provides invaluable information as to the
mechanism behind chronic stress-induced cerebrovascular dysfunction as well as
introduces the clinical consequences of said cerebrovascular dysfunction. With this being
said, there are several future directions this work could take.
Although successful at exploring this mechanism and clinical consequences,
future studies would benefit from exploring the direct impact of stress hormones (i.e.,
glucocorticoids and epinephrine) on XO. The studies presented here show that chronic
stress increases XO activity, however, the mechanism behind the increase of XO with
chronic stress have not been explored. Currently, little research has been conducted
regarding the impact of different stress hormones as it relates to XO activity; following this
train of research would provide more insight into chronic stress induced cerebrovascular
dysfunction and possibly provide different avenues of clinical relevance.
Inflammation has been implicated in cerebrovascular dysfunction with chronic
stress38–41 and data presented in chapter 4 provides insight into the role of inflammation
as it relates to driving the oxidative environment responsible for chronic stress-induced
cerebrovascular dysfunction. However, future studies will need to include assessments
of inflammation (i.e., ELISA, flow cytometry, RT-PCR for inflammatory cytokines). The
data obtained from these experiments will be instrumental in understanding the cyclic
effect between oxidative stress/XO and inflammation/TLR4. Based on data presented
here and extensive review of the literature, it would be logical to assume that chronic
stress would increase inflammation, further driving XO activity and oxidative stress,
resulting in cerebrovascular dysfunction; this theory would explain why removal of one
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component on this cycle (XO or TLR4) would prevent cerebrovascular dysfunction with
chronic stress.
Further, we begin to assess the impact of chronic stress in accelerating AD
pathology and the potential mechanism behind it. However, the data presented here only
assesses the role of chronic stress in accelerating cerebrovascular pathology with AD.
Future studies would benefit tremendously from assessing the impact of chronic stress in
accelerating typical AD pathology including Aβ and tau, as well as continuing the study
past 9 months in order to gain a complete understanding of the acceleration of AD
pathology with chronic stress. Based on the evidence presented here it is likely that
chronic stress would accelerate all AD pathology and as AD has been related to high
levels of serum uric acid19, it is also likely that febuxostat would help prevent this
acceleration. Additionally, as inflammation has been implicated as a central mechanism
in the development of AD42, it would also be beneficial to assess inflammation as it relates
to AD, chronic stress, and XO.
It is with this relationship between AD and inflammation and similarities between
AD and chronic stress cerebrovascular pathology that I propose the combination of a
TLR4 inhibitor in the paradigm described in chapter 5. Evidence in chapter 4 identifies
TLR4 in the mechanism of chronic stress-induced cerebrovascular dysfunction and the
literature identifies a role of TLR4 in AD43–45. With this knowledge, its logical to identify
the role of TLR4 in accelerating AD cerebrovascular pathology with chronic stress. As a
transgenic model is already being utilized to model AD, inhibition of TLR4 would have to
take place by means of chemical inhibition. TAK-242 is a small molecule that binds
selectively to TLR4 and interferes with TLR4 interactions with its adaptor molecules 46. It
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is well documented that TAK-242 prevents the development of a pro-inflammatory
environment but recent evidence shows that TAK-242 also prevents the development of
an oxidative environment47,48. This prevention of a pro-oxidative environment is aligned
with the data presented in this dissertation, suggesting that TAK-242 may be able to
prevent the accelerated AD cerebrovascular pathology with chronic stress.

Conclusion
Despite decades of research physiological stress remains a prevalent problem in
society, often diminishing quality of life and increasing the risk of developing
cerebrovascular diseases, such as dementia. The brain plays a central role in the
response to stress and is reliant on the cerebrovasculature for energy substrates
dynamically regulated through blood flow. It has been well established that chronic stress
induces cerebrovascular dysfunction and chronic stress increases XO activity, inducing
an oxidative environment. While the alterations have been well defined, there was no
evidence of a mechanism behind such alterations; therefore, there was a critical need to
identify the mechanism linking chronic stress and cerebrovascular dysfunction as well as
the potential role of the XO pathway.
This dissertation utilized pharmacological inhibition and manipulation of the XO
pathway, as well as global knockout of TLR4, a downstream target of XO, to provide
mechanistic insight into chronic stress-induced cerebrovascular dysfunction. We found
that inhibition and manipulation of XO prevents the development of an oxidative
environments and cerebrovascular dysfunction. Further, global knockout of TLR4
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prevented also prevented the development of an oxidative environments and
cerebrovascular dysfunction. Its important to note that inhibition, but not manipulation of
the XO pathway prevented cognitive impairment which led to the preliminary study
presented in the final chapter. Here, we assessed the role of chronic stress in accelerating
AD related cerebrovascular pathology and the role of XO in this dysfunction. We found
that chronic stress accelerates AD related cerebrovascular dysfunction and inhibiting XO
prevents this dysfunction.
Taken together, these data provide mechanistic insight into chronic stress-induced
cerebrovascular dysfunction. This data presented in this dissertation suggest that chronic
stress induces XO activity, which then activates TLR4, leading to a cyclic interaction
between XO and TLR; this cyclic relationship drives the development of a pro-oxidative
environment, leading to cerebrovascular dysfunction and cognitive impairment. Future
studies should utilize the work presented here to understand the potential clinical
consequences of chronic stress and AD.
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